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Abstract
INVESTIGATING THE ROLE OF ONCOGENE C-TERMINAL BINDING PROTEIN (CTBP)
IN PANCREATIC DUCTAL ADENOCARCINOMA

By Kranthi Kumar Chougoni

A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of
Philosophy at Virginia Commonwealth University

Virginia Commonwealth University, 2020
Advisor: Steven R. Grossman M.D, Ph.D.

The transcriptional coregulator CtBP2 has been implicated as an oncogene in colon, prostate,
breast and ovarian cancers. Previously, we reported overexpression of CtBP2 in human PDAC
specimens. However, its exact role in PDAC is still unclear. In the current study, we attempt to
delineate the oncogenic role CtBP2 in PDAC growth and metastasis. Using an orthotopic
syngeneic pancreatic tumor mouse model (CKP), we found that deletion of Ctbp2 decreases PDAC
tumor growth, proliferation, metastasis, EMT and significantly prolongs survival. Further, we
identified significant downregulation of Erbb3 mRNA levels upon deletion of Ctbp2 in CKP
PDAC cells As ErbB3 signaling was previously reported to play a critical role in pancreatic
tumorigenesis, we hypothesized that CtBP2 regulation of ErbB3 signaling at least, in part,
contributes to PDAC growth and metastasis. Upon mechanistic exploration, we found that CtBP2
interactor and Erbb3 regulator, Znp217, was concomitantly downregulated upon deletion of
Ctbp2. On the other hand, tumors obtained from Ctbp2 KO cohort showed a significant increase
in E-cadherin levels, recalling previous findings in breast cancer, and suggesting a possible role of
CtBP2 in epithelial-mesenchymal transition (EMT) in PDAC cells. In addition, in vitro tumor cell
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migration assays showed decreased CKP cell migration upon deletion of Ctbp2. Our findings
establish a dual oncogenic role of CtBP2 in PDAC growth, including through ErbB3/PI3K
regulation as well as EMT/metastasis via regulation of E-cadherin/PI3K signaling. In vitro studies
demonstrated increased cytotoxicity upon combining CtBP2 chemical inhibitors with ErbB3/PI3K
inhibitors. Our findings suggest new avenues to test CtBP2 inhibitors in combination with effective
ErbB3 or PI3K inhibitors as a novel treatment strategy to tackle metastatic PDAC.
In addition, we also attempted to demonstrate the oncogenic role of CtBP2 in the progression of
PDAC using a variation of the KPC pancreatic conditional mouse model that includes a
combination of mutated Kras with one allele of Tp53 deleted, which bears a close resemblance to
the genetic events that occur in human PDAC patients. CKP het mice develop precursor PanIN
lesions driven by oncogenic Kras, and with further allelic loss of p53, PanIN lesions progress to
PDAC with a latency period of 7-8 months. Based on previous reports showing that interaction
between CtBP2 and p14ARF (mouse p19ARF) leads to proteasomal degradation of CtBP2, and
preliminary data suggesting direct regulation of ARF by p38MAPK, we show that inhibition of
p38MAPK inhibitor treatment (SB 203580) in three-month-old CKP het mice greatly accelerates
the progression of PanINs to PDAC. Moreover, CtBP2 is upregulated in mice treated with
p38MAPK inhibitor, with a concomitant ablation of p19ARF levels. Our results suggest that
CtBP2 protein is intrinsically regulated by p38MAPK via p19ARF. Our work establishes a
putative role of the p38MAPK-p19ARF-CtBP2 axis in the regulation of PDAC progression. This
axis could be further explored to provide potential therapeutic advantage to PDAC patients. Due
to the druggable nature of CtBP2, we propose that a combination of CtBP2 inhibitors with p38
activators could be an effective treatment strategy to inhibit progression of PanINs to PDAC. We
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also caution against the use of p38MAPK inhibitors as anti-inflammatory agents in patients
predisposed to develop PDAC, as based on our data, this might trigger PDAC progression.
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1
1.1

Chapter 1: Introduction

Pancreatic Cancer

1.1.1 Biology of Pancreas
The pancreas is considered as a mixed gland composed of exocrine and endocrine portions. The
majority of the pancreas is exocrine (90-95%), including acini and ducts, and the endocrine portion
is composed of pancreatic islets or islets of Langerhans (Johansson & Grapin‐Botton, 2002). The
pancreatic acini are arranged in a lobular form, and secrete digestive enzymes released through
ducts into the common bile duct, which ends in the duodenum (Figure 1-1) (Pan & Wright, 2011).
Pancreatic islets are arranged in clusters of around 10-100 cells, which secrete metabolic hormones
like insulin, glucagon, somatostatin and pancreatic polypeptides directly into the blood (BastidasPonce et al., 2017). The two main functions of the pancreas are 1. to secrete the enzymes that aid
in the digestion of ingested food in the duodenum and 2. glucose metabolism by regulating release
of hormones (Leung & Ip, 2006).
The most common pathologic conditions of the pancreas are pancreatitis, diabetes mellitus
and pancreatic ductal adenocarcinoma (PDAC). Pancreatitis occurs mainly due to continuous
release and inappropriate activation of pancreatic enzymes like trypsin and amylase (Shah et al.,
2018). Multiple reports suggest that pancreatic cancer is driven by pancreatitis or pancreatitis is a
precursor event to pancreatic cancer (Li & Tian, 2017). However, there is no evidence that
pancreatitis is, itself, a cause of pancreatic cancer. On the other hand, diabetes mellitus is a
condition that results mainly from dysregulated insulin production by beta cells of pancreatic islets
(Kharroubi & Darwish, 2015), and late onset of type II diabetes, has been associated with PDAC,
more likely as an effect than a cause (Andersen et al., 2017). PDAC is the most aggressive form
of pancreatic cancer reported to originate from the exocrine pancreas. It is usually identified by
presence of interspersed ductal epithelium lying in a sea of stroma. The current chapter is focused
1

Chougoni 2020

on understanding the epidemiology, pathogenesis and current treatment options available for
PDAC.

Figure 1-1: Anatomy of normal human pancreas. Pancreas is divided into head, body and
tail. In the inset, lobular arrangement of acinar cells connected by ductal cells which transport
the enzymes secreted by acinar cells into the duodenum.

1.1.2 Epidemiology of Pancreatic Cancer
PDAC is the most common type of pancreatic cancer and accounts for 95% of all pancreatic
cancers (Cornelissen et al., 2018). Pancreatic cancer is the third most leading cause of cancer death
in the US (Ferlay et al., 2019). The five-year survival rate of PDAC patients after diagnosis is
below 10% (Rawla et al., 2019). The typical age group affected by pancreatic cancer is above 55
years (90% of cases), and it is very rarely seen in young adults (Midha et al., 2016; Wood et al.,

2
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2006). While the etiology of PDAC is still unknown, factors like familial history and consumption
of tobacco have been attributed to its development. (Bosetti et al., 2012; Klein et al., 2004).
1.1.3 Pathogenesis of Pancreatic Cancer
More than four decades of research had significantly improved our understanding of PDAC
progression. The cellular origins of PDAC still remains controversial, as different cellular lineages,
including acinar cells, ductal cells and nestin-expressing cells have been reported as progenitors
(Westphalen & Olive, 2012). However, the consensus in the field is that a multistep process of
genetic mutation starting with KRAS activating mutation is followed by inactivation of multiple
tumor suppressor genes in the cell of origin (Vogelstein & Kinzler, 2004). The genes most
commonly mutated in PDAC patients include the proto-oncogene KRAS (90% cases), and tumor
suppressors CDKN2A (>95% cases), TP53 (50-75%) and SMAD4 (55% cases) (Westphalen &
Olive, 2012).
As in other solid tumors, PDAC is characterized by the formation of precursor lesions prior
to invasive carcinoma (Distler et al., 2014). The acinar cells of the pancreas were reported to
transdifferentiate and acquire a ductal like phenotype under environmental (inflammation) and/or
oncogenic (mutations) stress leading to development of precursor lesions sensitive to further
oncogenic insults and transformation to invasive carcinoma (Orth et al., 2019). The process is
referred to as acinar-to-ductal metaplasia (ADM). The precursor lesions reported in pancreatic
cancer are mainly of three types 1) pancreatic intraepithelial neoplasia (PanINs) 2) intraductal
papillary mucinous neoplasms (IPMNs) and 3) mucinous cystic neoplasms (MCNs) which differ
morphologically (Ralph H Hruban et al., 2008). PanINs are the most common type of precursor
lesions observed in PDAC patients. PanINs are microscopic (typically less than 5mm) mucin
containing ductal like structures, usually cuboidal to columnar in shape, and are graded based on

3
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histological appearance (Saiki & Horii, 2014). PanIN lesions are classified into different grades
(I-III) based on the degree of dysplasia, with PanIN-IA/B being minimally dysplastic, PanIN II
showing increased cellular atypia with papillary structures, and PanIN III representing carcinoma
in situ, which further progresses to invasive carcinoma (Figure 1-2) (Hidalgo, 2010). On the other
hand, unlike PanINs, macroscopic IPMNs are cystic lesions that arise and branch out from the
main pancreatic duct, while MCNs are characterized by the presence of ovarian stroma and
mucinous epithelial lining, and they do not communicate with the pancreatic ductal system
(Iacobuzio-Donahue, 2012).

Figure 1-2: Transformation of normal mouse pancreas to PDAC via formation of PanINs.
Panel 1. H and E stained section of a normal mouse pancreas with lobular arrangement of acini
and basal nuclei stained in blue with hematoxylin and mucin stained in pink by Eosin dye. Panel
2. H and E section of pancreas showing A. PanIN 1 lesion with flat uniform nuclei B. PanIN grade
II with pleomorphic nuclei and columnar cells C. PanIN grade III lesions with pleomorphic nuclei,
nuclear overcrowding and papillary like structures. Panel 3. Representative H and E section of
mouse PDAC with desmoplasia and pleomorphism. Scale bar 50µm.

Activating KRAS mutations are found in 90% of PDAC cases (Güngör et al., 2014). KRAS is
considered a critical driver oncogene that initiates formation of PanINs. In normal cells, KRAS is
GDP bound and inactive, however, in the presence of extracellular stimuli, KRAS is active and
4

Chougoni 2020

GTP bound. When mutated, KRAS remains to in the GTP bound active state promoting excessive
growth of cancer cells independent of extracellular stimuli (Waters & Der, 2018). Additional
studies reveal KRAS mutations in PanIN-1 (specifically a point mutation on codon 12), inactivation
of tumor suppressor CDKN2A (an inhibitor of cyclin dependent kinase 4) in PanIN II, and
inactivation of TP53 and SMAD4/DPC4 rarely detectable in PanIN 3 (Güngör et al., 2014; R. H.
Hruban et al., 1993; Jones et al., 2008) (Figure 1-3). The progression of PanIN lesions to PDAC
results mainly due to loss of heterozygosity (LOH) observed in tumor suppressors like CDKN2A,
p53 and SMAD4 in micro dissected tumors (Heinmöller et al., 2000; Lüttges et al., 2001). PanINs
are histologically identified by the mucins expressed, with high grade PanINs specifically
expressing Muc 1, Muc 4, Muc 5AC and Muc 6 (Ralph H Hruban et al., 2008).

Figure 1-3: Stepwise molecular and genetic alterations driving the progression of PanINs to
PDAC. Adapted from (Distler et al., 2014).

Pancreatic cancer is further distinguished from other types of cancers by the presence of dense
stroma due to desmoplastic reaction (Chu et al., 2007). The formation of stroma is reported to be
contributed by the pancreatic stellate cells/myofibroblasts, and activated by growth factors like
TGF-beta, Platelet derived growth factor (PDGF) and fibroblast growth factor (Phillips, 2012).
5
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Tumor stroma has been proposed to promote tumor formation, progression and metastasis
(Rasheed et al., 2012) and hypothesized to be a key factor for the poor prognosis of the disease
and chemoresistance. Stromal cells express proteins like COX-2, VEGF and chemokines that
support tumor growth (Hidalgo, 2010).
Recently, studies targeting stroma were found to improve the effectiveness of
chemotherapeutic agents. Modified hyaluronidase (targets the extracellular matrix) when
administered with gemcitabine significantly prolonged the survival of KPC mice, and the
combination was tested in Phase III clinical trial (Jacobetz et al., 2013; Provenzano et al., 2012).
However, the trial was halted due several reasons (Doherty et al., 2017).
1.1.4 Mouse Models of Pancreatic Cancer
In the past two decades, several mouse models were developed in an effort to understand pancreatic
cancer progression. The majority of them were developed mainly based on the tissue specific
expression of mutant Kras, which is found in the majority of PDAC patients. Mouse models were
developed using Cre-LoxP system, using a construct containing a STOP site flanked by two LoxP
sites residing upstream of exon 1 of the KRAS gene with a G to D amino acid substitution at codon
12 (Kim et al., 2018). Expression of mutant KRAS is achieved in the mouse pancreas by
interbreeding LSL.KRASG12D mice with mice that express bacterial cre-recombinase under the
control of the PDX-1 promoter (a transcriptional factor required for the development of the
pancreas). The resulting “CK” mice are born with mutant Kras expression in the pancreas
(Hingorani et al., 2003). CK (Pdx-1-Cre; LSL.KrasG12D) mice develop precursor lesions that
progress to adenocarcinoma in approximately two years. Thus, the importance of KRAS mutations
in initiating the pancreatic cancer progression was established. Interestingly, a cohort of KrasG12D

6
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mice did not develop adenocarcinoma but died due to other complications. This suggested CK
mice were not ideal to study the progression of PDAC due to poor penetrance.

In order improve penetrance of PanINs to PDAC progression in the CK model, the model was
further modified by inclusion of deletions in tumor suppressor genes like TP53, CDKN2A and
SMAD4. This resulted in generation of mice that rapidly progress from precursor lesions to
adenocarcinoma. For example, LSL.K-RasG12D with homozygous deletion of CDKN2A resulted in
rapid development of adenocarcinoma, which is highly metastatic (Aguirre et al., 2003). This
model helped in understanding the roles of other tumor suppressors in pancreatic tumor
progression. For our studies, we used two mouse models to understand the progression of
pancreatic adenocarcinoma, 1. Pdx1-Cre; LSL.KrasG12D p53flox/flox referred to as CKP, with a
median survival of 8.8 weeks that develop highly metastatic adenocarcinoma and 2. Pdx1-Cre;
LSL.KrasG12D p53+/flox referred as CKP het with a median survival of 20 weeks, that develop
adenocarcinoma in 7-8 months.
However, certain shortcomings were reported with these models. Firstly, in order to
quickly develop adenocarcinoma, the genetic insults are applied at the same time while pancreatic
cancer progression is considered to be stepwise. Reports suggest that the tumors which develop
quickly are not completely similar to human PDAC (Westphalen & Olive, 2012). In addition, the
desmoplastic reaction which is seen only in some mouse PDAC models is not to the extent
observed in humans (Westphalen & Olive, 2012) . The question of fidelity and usability is the
issue with many transgenic mouse models.
In addition, xenograft mouse models were developed mainly for preclinical testing of
drugs. They help in understanding the effect of the treatment on tumor cells; however, they don’t

7
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describe the role of host tumor interactions (Herreros-Villanueva et al., 2012). Drugs which were
effective in subcutaneous xenografts often failed to be effective in actual human patients
(Herreros-Villanueva et al., 2012).
The experience with xenograft models was followed by the development of orthotopic
PDAC models which try to mimic actual pancreatic tumors. There has been considerable success
with this model. However, the development of an orthotopic model requires special surgical skills
to accurately inject the PDAC cells into the mouse pancreas (Herreros-Villanueva et al., 2012).
To study CtBP2’s role in PDAC growth, we developed an orthotopic model in chapter 2,
by injecting a PDAC cell line with luciferase expression into the pancreatic tail vein. The
advantage of this model is ability to track the tumor growth and metastasis with a bioluminescent
marker.

1.1.5 Treatment Challenges and Therapeutic Options
The two most common treatment strategies for pancreatic cancer patients are
1) surgical resection and
2) Chemotherapy or neoadjuvant therapy (A. Chawla & Ferrone, 2019)
Several challenges posed in the treatment of pancreatic cancer are:
1) patients present with symptoms mostly at an advanced, metastatic, stage of disease
2) lack of biomarkers that could help predict prognosis of the disease
3) dense fibrotic tumor microenvironment due to myofibroblasts and immune cells around the
tumor cells making it difficult for drugs to access tumor cells (Zhu et al., 2018)
4) chemoresistance phenomenon exhibited by tumor cells (Sheikh et al., 2010)
8
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Some of the established therapies include gemcitabine or FOLFIRINOX (5-flurouracil,
leucovorin, irinotecan, and oxaliplatin) (Thibodeau & Voutsadakis, 2018). In the definitive clinical
trial, the overall median survival in the FOLFIRINOX treated group was 11.1 months while the
gemcitabine alone treated group survived 6.8 months. The combination of gemcitabine-(albumin
bound)nab -paclitaxel also showed a significant survival benefit for PDAC patients vs.
gemcitabine alone (Von Hoff et al., 2013). The epidermal growth factor receptor (EGFR) inhibitor
erlotinib was approved by FDA for the treatment of pancreatic cancer and was reported to provide
survival benefit in patients when combined with gemcitabine (Kelley & Ko, 2008). However, due
to severe adverse effects resulting from the combination drugs, there was only very modest
improvement in the survival of PDAC patients (Adel, 2019). Indeed, the quality of life of PDAC
patients is very poor due to severe side effects of the available therapies as well as the symptom
burden of the cancer.
Though several therapies already exist in the market to treat pancreatic cancer, only limited success
is observed with these therapies. There is an urgent need to develop novel therapies to treat
pancreatic cancer. Research over several decades has barely improved the survival of PDAC
patients, underscoring the importance of research to improve outcomes in pancreatic cancer.
Chapter 2 of my dissertation will explore strategies to develop novel therapies to treat pancreatic
cancer.

9
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1.2

C-terminal Binding Proteins (CtBPs)

1.2.1 Discovery of CtBPs
While examining adenoviral early proteins for their oncogenic properties, G. Chinnadurai’s group
identified a 48kDa phosphoprotein that binds to the C-terminal region of adenovirus E1A altering
its oncogenic transformation properties (Boyd et al., 1993). When cloned and characterized, it was
reported that C-terminal Binding Protein (CtBP) possessed a domain that interacted with a unique
conserved short sequence motif (PLDLS) within the E1A protein (Schaeper et al., 1995, 1998).
Upon further examination, it was identified that CtBP shared a significant homology with NAD
dependent D-2-hydroxy acid dehydrogenases (Schaeper et al., 1995; Taguchi & Ohta, 1991).
These findings predicted CtBP could possess enzymatic activity that could potentially alter
oncogenic transformation (Turner & Crossley, 2001). On the other hand, a novel gene, highly
similar to CtBP1 and ubiquitously expressed, termed CtBP2, was also identified (Katsanis &
Fisher, 1998). When mapped to the human genome, CtBP1 was found on chromosome 4p16 and
CtBP2 on chromosome 21q21.3.
CtBP proteins are evolutionarily conserved among both invertebrates and vertebrates.
CtBP exists as a single gene in lower invertebrates like Drosophila, Xenopus and Caenorhabditis
elegans. It exists as two paralogs (CtBP1 and CtBP2), which share a high degree of similarity, in
mammals, such as rodents and humans (Chinnadurai, 2002; Katsanis & Fisher, 1998). However,
different forms of CtBP1 and CtBP2 exist mainly due to differential RNA splicing. The CtBP1
gene encodes two isoforms, CtBP1-L (Long form) and CtBP1-S (Short form), and CtBP1-S is also
referred to as CtBP1/BARS (Brefeldin A-ADP ribosylated substrate), which localizes to the
cytoplasm due to the deletion of N-terminal amino acids (Verger et al., 2006). CtBP1 was also
reported to regulate Golgi membrane fission during mitosis and lipid storage (Bartz et al., 2007;
Corda et al., 2006). CtBP2 exists in three isoforms CtBP2-S, CtBP2-L, and RIBEYE protein. The
10
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CtBP2-L and CtBP2-S forms are nearly identical, with an extended N-terminus in the long form
(Dcona et al., 2017). However, RIBEYE is a synaptic protein expressed only in the retina, and
contains a large alternatively spliced N-terminus (Chinnadurai, 2002). As can be seen by these
unique vs. common isoforms and functions, CtBP 1 and 2 possess both redundant and unique
functions.

1.2.2 Structure of CtBP1 and CtBP2
The typical structure of CtBP proteins can be divided into three regions: N-terminal, C-terminal
and a dehydrogenase domain.
N-terminal Domain: The N-terminal region of CtBP is mainly responsible for interaction with
the other transcriptional factors. It possesses a binding domain for a PxDLS (Pro-x-Asp-Leu-Ser,
x-hydrophobic amino acid) motif present in many transcriptional factors (Quinlan et al., 2006).
Transcriptional factors like HDACs (HDAC 4, 5 & 7) possess this unique PxDLS motif, to which
CtBPs bind to promote transcriptional repression. Other transcriptional factors like KLF 3, 8 and
12 binds to CtBP via their PvDLS motifs (van Vliet et al., 2000). Thus, the transcriptional role of
CtBP was attributed to the unique ability of the N-terminus to bind these PxDLS motifs. In
addition, CtBP2 possesses a unique Nuclear Local Signal (NLS) amino acid sequence also at the
N-terminus, that aids in nuclear retention (Chinnadurai, 2002).
Dehydrogenase Domain: As mentioned previously, CtBPs show structural similarity to NADdependent D-2-hydroxyacid dehydrogenases (Lundblad, 2013). The dehydrogenase domain of
CtBPs can be further divided into a Nucleotide Binding Domain (NBD), to which NAD binds, a
Catalytic Domain (CD), and an RRT motif with the ability to bind to other transcriptional factors
(Figure 1-4). The dehydrogenase domain of CtBP resembles “Rossman Fold” topology found in
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bacterial dehydrogenases. It also contains a catalytic triad of amino acids that are considered vital
for substrate binding and catalytic activity (Dcona et al., 2017). NADH binding to the
dehydrogenase domain leads to dimerization or tetramerization of CtBP proteins to promote
transcriptional regulation in hypoxic cancer cells (Jecrois et al., 2020)
C-terminal Domain: The CtBP C-terminus was initially considered to have no functional
significance. Hence, most of the studies performed initially did not include the C-terminus.
However, studies performed later justified that the C-terminus is particularly proline/glycine rich,
which resulted in a difficulty to crystallize and an unstable nature (Dcona et al., 2017). The Cterminus is responsible for interaction with tumor suppressor proteins like Alternate Reading
Frame (ARF) that lead to degradation of CtBP2 (which will be discussed in detail later in the
chapter) (Kovi et al., 2010). The C-terminus of CtBP1 possesses a unique PDZ domain, absent in
CtBP2, that promotes cytoplasmic localization of CtBP1 (Stankiewicz et al., 2014).

Figure 1-4: Structure of CtBP1 and CtBP2 proteins. The two most conserved domains of CtBPs
are the PxDLS binding domain, which binds to transcriptional factors, and the dehydrogenase
domain, where NADH binds, leading oligomerization of CtBPs. CtBP1 possesses a unique PDZ
domain, which promotes cytoplasmic retention and CtBP2 possesses a nuclear localization signal,
which aids in nuclear retention (Adapted from (Stankiewicz et al., 2014)).
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1.2.3 CtBPs as transcriptional co-repressors
Transcriptional tethering assays have revealed the transcriptional corepressor activity of CtBPs
(Sollerbrant et al., 1996). These assays were performed by fusing E1A domains to the DNA
binding Gal4 domain. Upon inclusion of the C-terminal region of E1A (CR3) in the chimeric Gal4E1A construct, CR1 mediated transactivation was abrogated, while deletion of the C-terminal
binding motif (CR3) relieved the repression. Thus, CtBP was first discovered as a transcriptional
repressor. Later, studies performed in Drosophila (dCtBP) confirmed the transcriptional
corepressor activity of CtBP (Nibu et al., 1998; Poortinga et al., 1998). In Drosophila, CtBP was
identified interacting with transcriptional DNA binding repressors like Knirps, Snail, and Kruppel,
and their repression was dCtBP mediated. These studies highlighted the importance of the PxDLS
binding domain in CtBPs interaction with other transcriptional factors. In mice, CtBPs interaction
with basic kruppel like factors was also dependent on PxDLS motifs (Turner & Crossley, 2001).
By performing a yeast two hybrid screening assay several other transcriptional repressors
interacting with CtBP2 were identified (Vo et al., 2001).

1.2.4 Mechanism of transcriptional repression by CtBP
The comprehensive understanding of CtBPs structure helped in the understanding of CtBP
mediated transcriptional repression. CtBP was reported to oligomerize in the presence of NAD+
and bind to a transcriptional repressor complex (both HDAC dependent and independent) to
promote gene repression (Figure 1-5) (Balasubramanian et al., 2003; Dcona et al., 2017). NADH,
which binds to dehydrogenase domain, was considered to be essential for the CtBPs activity, and
mutations in the dehydrogenase domain diminished CtBPs ability to perform transcriptional
repression (Kumar et al., 2002). NADH levels in a cell are dependent on the metabolic status of
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the cell, for example hypoxic cancer cells exhibit high levels of NADH, and contain higher levels
of CtBP activity (Q. Zhang et al., 2006). Thus, due to the role of hypoxia in tumor progression, a
possible role of CtBPs in cancer cell growth was identified (Q. Zhang et al., 2006).

Figure 1-5: Proposed mechanism of transcriptional repression by CtBP2. CtBP in the
presence of NADH dimerizes and interacts with transcriptional repressor ZEB1/2 and complexes
with co-repressor complex (HDACs, CoREST, etc.) to promote gene repression.

1.2.5 Biological roles of CtBPs
The biological roles of CtBPs vary by species, CtBPs are an evolutionarily conserved family of
proteins present from plants to humans. An ortholog of the CtBP gene, AN (ANGUSTIFOLIA) is
present in plants and reported to be essential for regulating stress responses and other important
functions like flowering, seed production and microtubule polarity (Gachomo et al., 2013). Studies
in Drosophila revealed that loss of dCtBP leads to severe segmentation defects, and homozygous
inactivation of CtBP is embryonically lethal (Poortinga et al., 1998). The defects in Drosophila
were attributed to the loss of repression of target genes, revealing the requirement for dCtBP in
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normal growth and development. Similarly, in Xenopus embryos transcriptional factors xTcf-3,
xFOG and ZEB-2/SIP1 were shown to interact with xCtBP. When xCtBP was ectopically
expressed, defects were noted in the head and notochord revealing the essential role of CtBP
(Chinnadurai, baron et al. 1999). Studies in C. elegans showed that CtBP is required for regulation
of lipids, by repressing the enzymes lipase and lips-7, thereby enhancing life span (S. Chen et al.,
2009).
In vertebrates, CtBP is required for normal growth and development. Knockdown studies
conducted in mouse embryos with deletion of CtBP1 resulted in mice that were small and viable,
whereas CtBP2-null mice did not survive beyond 10.5 days (Hildebrand & Soriano, 2002). When
one allele of CtBP2 is deleted in CtBP1 null mice, this led to multiple developmental defects and
death in the uterus (Hildebrand & Soriano, 2002). These studies suggested that CtBP2 and CtBP1
might have both unique and overlapping roles (L. M. Bergman et al., 2006). CtBPs were also
reported to regulate mitotic fidelity, inhibition of CtBP synthesis lead to aberrant segregation of
chromosomes due to decreased association of aurora B with mitotic chromatin (L. M. Bergman et
al., 2009). In a recent report, CtBP2 was shown to be essential for the development of mouse
cerebral cortex (Karaca et al., 2020) .
A study performed on quail embryos further revealed the importance of CtBPs in vertebrate
development, where CtBPs were reported to be essential for the limb bud and neural development
(Van Hateren et al., 2006). Other functional roles of CtBPs in vertebrates include mitochondrial
maintenance in cancer cells through regulation of glutaminolysis by interacting with SIRT4, and
regulation of fat differentiation through repression of white fat genes (Kajimura et al., 2008; L.
Wang et al., 2015).
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The important aspect relevant to the current chapter is the role of CtBPs in various cancers.
CtBP1/2 were shown to repress the several tumor suppressor genes to promote tumor cell
proliferation, survival and metastasis which will be discussed in detail below (Stankiewicz et al.,
2014).

1.2.6 Role of CtBPs in cancers
CtBP1/2 are often overexpressed and associated with poor prognostic outcomes in colon, breast,
ovarian, gastric and prostate cancers (Barroilhet et al., 2013a; Bizama et al., 2014; Yu Deng et al.,
2012; Straza et al., 2010; R. Wang et al., 2012). The detailed mechanistic roles of CtBP in various
cancers are discussed below and summarized (Figure 1-6) and (Table 1).

1.2.6.1 Role of CtBPs in apoptosis
Regulation of apoptosis is one of the key mechanisms for survival of cancer cells. CtBPs have
been shown to promote transcriptional repression of pro-apoptotic genes. Knockout studies in
MEFs showed that deletion of CtBP1/2 relieved the repression of apoptotic genes like PERP, p21,
Noxa, and Bax (M Grooteclaes et al., 2003). Later, studies performed in our lab confirmed the
findings in MEFs. Upon transient knockdown of CtBP2 in colorectal cancer cells, the proapoptotic gene Bik gene was upregulated along with increased cleaved caspase 3 levels, an
indicator of apoptosis (Kovi et al., 2010; Straza et al., 2010). We also reported that CtBP2
inhibitors induce apoptosis in colorectal, ovarian and breast cancer cell lines (Korwar et al., 2016).

1.2.6.2 CtBPs role in EMT/Metastasis of cancer cells
EMT is a phenomenon in which epithelial cells acquire mesenchymal properties and enhanced
migratory capacity (Kalluri & Weinberg, 2009). During EMT, it is often reported that cells
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downregulate the cellular adhesion marker E-cadherin, which facilitates migration of cells from
the primary tumor site to distant organs (Gheldof & Berx, 2013). Studies in MEFs reported that
knock down of CtBP1/2 led to the upregulation of epithelial markers E-cadherin and keratin-8
consistent with the reverse mesenchymal-epithelial transition (MET) (M Grooteclaes et al., 2003).
Similar studies were conducted in breast cancer cells known to have undergone EMT, where
transient knockdown of CtBP1 caused restoration of E-Cadherin gene expression (Yu Deng et al.,
2012). In addition, CtBP2 overexpression was reported to induce EMT in gastric cancer (Dai et
al., 2017).These findings underscore the key role of CtBP 1 and 2 in EMT (Eskiizmir & Özgür,
2018).
Several genes that regulate cancer cell migration interact with CtBP, including T-lymphoma
invasion and metastasis-inducing-1 (TIAM1). Tiam1 promotes tumor cell migration and its
expression is positively correlated with CtBP2 protein levels (Seema Paliwal et al., 2012).
Transient knockdown of CtBP2 in human colorectal and lung cancer cells resulted in
downregulation of TIAM1 mRNA and protein levels that correlated with decreased migration rate.
However, CtBP2 in this context is referred to as transcriptional co-activator not repressor. Thus,
CtBPs roles as a transcriptional regulator is context dependent, but ultimately promoting
oncogenesis. Additionally, tumor cell migration is often associated with increases in PI3K/AKT
signaling, and tumor suppressor PTEN has been reported to downregulate PI3K signaling and
migration. Overexpression of CtBP2 was reported to downregulate PTEN, resulting in increased
PI3K/AKT signaling in HCT116 cells (Seema Paliwal et al., 2007). In addition, CtBP2 was shown
to repress tumor suppressor PTEN expression in gastric cancer (Dai et al., 2017).
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1.2.6.3 CtBP2 and p14ARF interaction
Alternate Reading Frame (ARF) is a tumor suppressor, and an MDM2 antagonist that inhibits the
degradation of p53, thereby promoting p53 dependent apoptosis (Gallagher et al., 2006). ARF is
inactive in normal cells, but oncogenic or environmental insults activate ARF, resulting in cell
apoptosis, senescence or cell cycle arrest (Ozenne et al., 2010). Earlier studies reported the
interaction between p14ARF and CtBP2 in human colon cancer cells. The interaction resulted in
proteasomal mediated degradation of CtBP2, and ARF mediated apoptosis in colon cancer cells
was dependent on its interaction with CtBP2 (S Paliwal et al., 2006). CtBP2 and p14ARF
interaction was later found to relieve BH3 proapoptotic gene expression leading to induction of
apoptosis, a key feature regulating the tumor cell survival (Kovi et al., 2010). This was further
confirmed by a study in which p14ARF levels varied inversely with CtBP2 protein in human
colorectal cancer patients (Straza et al., 2010). This study established the inverse relationship
between p14ARF and CtBP2 in human tumors. As ARF was previously reported to be involved in
regulation of cancer stem cell growth and tumor cell dormancy, this suggested possible
involvement of CtBP2 in cancer stem cell (CSC) maintenance and self-renewal.

1.2.6.4 CtBPs in cancer stem cells growth and self-renewal
Upon examining the role of CtBP2 in cancer stem cells, it was reported that overexpression of
CtBP2 is associated with increased CSC growth and self-renewal. In addition, chemical inhibition
of CtBP2 specifically targets colon spheres, which possess cancer stem cell characteristics (Patel
et al., 2014b). In this work, CtBP2 regulation of TCF4 signaling was found to promote cancer stem
cell formation. However, the exact role of CtBP in regulation of TCF-4 signaling needs further
investigation. Studies in breast cancer reported that transient knock down of CtBP2 leads to
decrease in CD44/CD24 (cancer stem cell markers) levels. Further overexpression of CtBP2,
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increased levels of CD44/CD24, demonstrating CtBP2’s ability to promote cancer stem cell
marker expression. In a report from our lab we showed decreased tumor initiating cells (cancer
stem cells) upon allelic loss of Ctbp2 in the Apcmin mouse model characterized by intestinal
polyposis (A. T. Chawla et al., 2018). Similarly, in a PDAC mouse model we observed that allelic
loss of CtBP2 downregulates oncoprotein c-Myc levels, a critical regulator of tumor initiating cell
activity (TIC; another term for CSC) (A. T. Chawla et al., 2019). Thus, the above reported studies
confirm the critical role of CtBP2 in cancer stem cell growth and self-renewal in various cancers.

1.2.6.5 CtBPs in Wnt signaling
Wnt signaling is considered as one of the key pathways regulating cancer cell growth (Zhan et al.,
2017). Major players in Wnt signaling include -catenin and the APC complex (that includes
Adenomatous Polyposis Coli (APC), Axin1/2, and GS3K). In normal cells with wild type APC, catenin is unstable due to constitutive proteasomal degradation. However, in cancer cells with
mutated APC, there is abrogation of beta-catenin degradation by APC, increasing −catenin levels
and upregulating tumor cell growth and proliferation. In the presence of Wnt ligand, -catenin is
stabilized, migrates to the nucleus and upregulates c-Myc levels to promote cell growth. When
CtBP’s role in Wnt signaling was explored, it was shown that CtBP played a dual role in Wnt
signaling. CtBP was reported to antagonize APC mediated TCF4 signaling by sequestering bcatenin and preventing its nuclear export from cytoplasm (Hamada & Bienz, 2004). On the other
hand, CtBP oligomerizes in the presence of mutant APC and favors the release of -catenin,
promoting c-Myc signaling and tumor cell growth (Schneikert et al., 2011).
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1.2.6.6 Regulation of BRCA1/2 by CtBPs
Tumor suppressors BRCA1/2 are known for their DNA repair function, and mutations/deletions
in BRCA1/2 were often reported in many cancers, more frequently in breast and ovarian cancer,
where inherited mutations cause early onset breast and ovarian cancer (Silver & Livingston, 2012).
CtBP dynamically regulates expression of BRCA1, targeting a metabolically regulated repressive
complex to the BRCA1 promoter (Di et al., 2010). CtBP1 was also shown to repress BRCA1
expression by binding to the E2F4 site of its promoter region in head and neck cancers (Y Deng et
al., 2010), and overexpression of CtBP2 has been shown to represses BRCA1 gene expression in
ovarian cancer cells (May et al., 2013). Further, studies in human breast cancer showed that CtBP1
interacted with slug repressor protein to repress BRCA2 expression (Tripathi et al., 2005). To
summarize, sufficient evidence demonstrates CtBP regulation of BRCA1/2 expression in breast,
ovarian and head & neck cancers, emphasizing the potential importance of targeting CtBP in
cancers where BRCA1/2 are epigenetically regulated by CtBP overexpression.
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Figure 1-6: Multiple oncogenic roles of CtBP1/2 in cancer. CtBP1/2 repress multiple tumor
suppressors like PTEN, BRCA1, E-cadherin and pro-apoptotic genes to ultimately promote
tumor cell growth proliferation, survival and EMT/metastasis.
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Table 1: Summary of CtBP1/2 roles in various cancers
CtBP isoform

Cancer

Role

CtBP1/2

Prostate Cancer

Essential for tumor cell growth,
proliferation (R. Wang et al., 2012),
associated with angiogenesis and
apoptosis (Xuan et al., 2017)

CtBP2

Colon Cancer

Inhibition of CtBP2 targets Colon cancer
cells (Straza et al., 2010); Promotes CSC
growth and self-renewal (Patel et al.,
2014b)

CtBP2

Pancreatic Cancer

Loss of CtBP2 prolongs survival of CKP
mouse with PDAC (A. T. Chawla et al.,
2019)

CtBP 1/2

Ovarian Cancer

Deletion of CtBP2 suppressed tumor cell
growth and migration (Barroilhet et al.,
2013b); overexpression of CtBP2
correlates with poor prognosis (May et
al., 2013); repression of DR4/5 receptors
(B. Ding et al., 2020)

CtBP2

Gastric Cancer

Overexpression of CtBP2 associated
with induction of EMT and repression of
tumor suppressor PTEN (Dai et al.,
2017)

CtBP1/2

Breast Cancer

Promotes EMT by repressing E-cadherin
and PTEN gene expression (Zhao et al.,
2019); transcriptional downregulation of
BRCA1 expression (Yu Deng et al.,
2012); promotes tumor cell survival by
maintaining mitotic fidelity which is lost
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upon deletion leading to apoptosis (L.
Bergman & Blaydes, 2006)

1.2.7 Chemical inhibitors of CtBP2
The uniqueness of CtBPs when compared to other transcriptional factors is mainly due to the
presence of a druggable dehydrogenase domain. CtBP contains a dehydrogenase domain to which
NAD(H) and a putative substrate 4-methylthio-2-oxobutyric acid (MTOB) binds, and it converts
MTOB to 4-methylthio-2-hydroxybutyric acid (MTHB) along with NADH to NAD+ conversion
(Figure 1-7) (Achouri et al., 2007) MTOB acts as a substrate inhibitor at higher concentrations
and disrupts CtBP functions (Achouri et al., 2007; Straza et al., 2010). When the mechanism of
action of MTOB was probed, it was found that MTOB displaced CtBP from the promoter region
of the pro-apoptotic gene BIK, resulting in apoptosis of HCT116 colon cancer cells (Kovi et al.,
2010; Straza et al., 2010). When the effectiveness of MTOB was tested in vivo, a significant
decrease in tumor burden was observed in mice xenografted with colon cancer cells (Straza et al.,
2010). In addition, MTOB was shown to specifically target colon cancer stem cells by inhibition
of TCF4 signaling (Patel et al., 2014a). These studies highlighted the use of CtBP2 inhibitors as
anti-cancer agents.
However, MTOB was effective only at very high concentrations, suggesting further need to
develop more potent and specific CtBP2 inhibitors. The X-ray crystallographic structure of the
CtBP/NADH/MTOB complex has assisted the development of new CtBP2 inhibitors by
modification of the existing functional groups (Hilbert et al., 2014). The first compound developed
after MTOB was phenyl pyruvate, which was three times more effective as a CtBP inhibitor than
MTOB as determined by NADH consumption assay (Korwar et al., 2016). When the ketone group
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in phenyl pyruvic acid was substituted by different functional groups and tested for the inhibition
of dehydrogenase activity, hydroxyimine-substituted phenyl pyruvate and derivatives (HIPPs)
were identified as the most effective CtBP inhibitors, with an IC50 of 0.24µM for HIPP (Korwar
et al., 2016). Treatment of Apc

min

mice, which succumb to massive intestinal polyposis, with

HIPP, resulted in a significant decrease of polyp burden, phenocopying Ctbp2 haploinsufficiency
(Evan T. Sumner, 2016).
With further efforts to improve HIPP’s potency, chlorination of the phenyl group resulted in
inhibitors more effective than the parent HIPP (Korwar et al., 2016). Thus, one of the most potent
inhibitors of CtBP2 developed so far is 4-chloro-hydroxy-imino-phenyl-pyruvate (4-Cl HIPP). 4Cl HIPP has been shown to induce apoptosis in colon, ovarian and breast cancers (shown in
Appendix 1). In a recent report, 4-Cl HIPP shown to decrease the tumor burden in CKP mice with
PDAC tumors, and induce apoptosis in tumors when combined with gemcitabine (A. T. Chawla
et al., 2019).

Figure 1-7: Putative mechanism of CtBP2 inhibitors. Reduction of CtBPs putative substrate
MTOB to MTHB upon conversion of NADH to NAD+. Inhibitors of CtBP2 impede the conversion
of NADH to NAD+, with induction of apoptosis in tumor cells(Adapted from (Dcona et al., 2017)).
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1.3

Overview of dissertation

Chapter 1 of this dissertation discusses the biology of the pancreas with special emphasis on key
aspects of pancreatic cancer. Further, Chapter 1 discusses the pathogenesis of pancreatic cancer,
along with available therapeutic options and challenges in the treatment of PDAC patients. The
second half of the chapter details the discovery, structure and multiple roles of CtBPs, especially
in cancer, as well as the importance of CtBP inhibitors as therapeutic agents to treat cancers. Lastly,
Chapter 1 presents the rationale for the proposed studies in the dissertation.

Chapter 2 discusses the oncogenic role of CtBP2 in PDAC growth and EMT. In a recent report
from our lab entitled “CtBP- a targetable dependency for pancreatic ductal adenocarcinoma”, we
documented that deletion of CtBP2 prolonged survival and decreased metastatic tumor burden in
CKP mice with PDAC tumors. However, the mechanism by which CtBP2 regulates PDAC growth
and metastasis is not clearly understood. In Chapter 2, we attempt to explain the oncogenic role
of CtBP2 in PDAC growth and EMT by proposing the following specific aims:
Aim 1: To generate a mouse cell line model that recapitulates human PDAC and suitable for
manipulating CtBP2 levels
Aim 2: To understand the impact of CtBP2 loss on PDAC tumor growth and EMT
Aim 3: To test the translational potential of CtBP2 inhibitors in combination with EGFR/PI3K
inhibitors
For these studies, we generated a mouse PDAC cell line from CKP mouse tumors and
knocked out CtBP2 using CRISPR Cas9 technology. To understand the impact of CtBP2 loss on
PDAC growth and signaling pathways, we orthotopically injected CKP cells into the pancreas of
NSG mice and compared tumor growth between the CKP WT and CtBP2 KO orthotopic allograft
cohorts. We discovered that deletion of CtBP2 downregulated ERBB3/PI3K signaling that
25

Chougoni 2020

possibly controls PDAC growth and EMT. To test the translational implication of our finding, we
rationalized dual inhibition CtBP2 and EGFR/PI3K as a potential strategy to treat PDAC. Our
results established a novel role of CtBP2 in regulating PDAC growth and EMT via ERBB3/PI3K
signaling that could be targeted for treating PDAC.

In chapter 3, we explored the role of the p38MAPK-ARF-CtBP2 axis in progression of PDAC.
Previously, tumor suppressor p14ARF was shown to interact with CtBP2 leading to the
proteasome-mediated degradation of CtBP2. In an unpublished study, we have found that
degradation of CtBP2 by p14ARF was dependent on activation of p38MAPK signaling (R.
Boothello, K. Chougoni, S.R. Grossman, B.P. Patel, unpublished). Due to the vital role played by
p38MAPK in PDAC, we hypothesized the existence of a p38-ARF-CtBP2 axis role in progression
of PDAC. We proposed the following aims to test our hypothesis:
Aim 1: Determine the effect of p38 inhibition on progression of PDAC
Aim 2: Determine if the p38/ARF/CtBP2 axis is disrupted upon inhibition of p38MAPK
Aim 3: Determine effect of p38 activators in combination with CtBP2 inhibitors on PDAC
progression
We generated a “CKP het” transgenic model, where mice develop PanIN lesions in the
pancreas which progress to PDAC in several months. Later, we observed that inhibition of
p38MAPK phosphorylation using the chemical inhibitor SB203580 accelerated the conversion of
PanIN lesions to PDAC at a much earlier age than expected for the strain. When we attempted to
delineate the role of the p38-ARF-CtBP2 axis in progression of PDAC, we discovered that
inhibition of p38 interfered with proteasomal degradation CtBP2 protein by p19Arf. Our findings
propose the use of p38 activators in combination with CtBP2 inhibitors as a prevention strategy
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for pancreatic cancer progression. In addition, our study cautions against the use of p38 inhibitors
as anti-inflammatory agents in patients who are predisposed to develop PDAC.

Chapter 4 draws conclusions from the findings in Chapters 2 and 3, and suggests future studies
needed to gain a comprehensive understanding of CtBP2’s role in PDAC.

27

Chougoni 2020

1.4

Rationale for the studies
Adapted from

Chawla, A.T., Chougoni, K.K., Joshi, P.J. et al. CtBP—a targetable dependency for tumorinitiating cell activity and metastasis in pancreatic adenocarcinoma. Oncogenesis 8, 55 (2019).
https://doi.org/10.1038/s41389-019-0163-x
The rationale for the proposed research is based on a recent finding in which we reported CtBP as
a targetable dependency to treat pancreatic adenocarcinoma. We documented a uniformly high
expression of CtBP 1 and 2 proteins in human PDAC specimens at various stages. (Figure 1-8).
However, upon immunohistochemical staining, tumor portions of PDAC specimens revealed a
higher expression of CtBP2 when compared to the normal ducts. To understand the role of CtBP2
in PDAC, we developed a transgenic CKP (Pdx1-Cre.LSL.KrasG12D.p53flox/flox) model that closely
mimics metastatic PDAC. An allelic loss of Ctbp2 in CKP mice (Pdx-1. Cre. LSL. KrasG12D.
p53flox/flox. Ctbp2+/- known as CKP2 mice) significantly prolonged survival and decreased
metastatic tumor burden (Figure 1-8). This finding was in close agreement with our previous
report that Apc

min

mice with deletion of an allele of Ctbp2 had significantly prolonged survival

and decreased polyposis compared with the parent Apc min strain (Evan T. Sumner, 2016). This led
to investigation of the contribution of Ctbp2 to PDAC growth and metastasis.
Previous studies highlighted the role of the proto oncogene c-Myc in progression of PanINs
to PDAC, and for the formation of self-renewing Tumor Initiating Cells (TICs) (Hessmann et al.,
2016). Given the c-Myc dependency on CtBP2 expression in prostate cancer (C. Zhang et al.,
2014), we sought to probe for impact of Ctbp2 loss on c-Myc protein expression in the CKP2 mice.
We found that levels of c-Myc along with CD-133, a tumor initiating cell (TIC) marker,
dramatically decreased upon allelic loss of Ctbp2 (Figure 1-9). This finding suggested the possible
role of CtBP2 in maintaining the stemness of PDAC, a possible reason for decreased metastasis
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observed upon allelic loss of Ctbp2. However, it’s unclear whether CtBP2s regulation of c-Myc in
PDAC is direct or indirect. As CtBP2 is druggable, we tested the efficacy of the CtBP2 inhibitor
4-Cl HIPP either alone, or in combination with gemcitabine, a popular chemotherapeutic agent.
We found that treatment of CKP mice with the combination of CtBP2 inhibitor and gemcitabine
resulted in significant decrease of tumor size, when compared to vehicle or gemcitabine or 4-Cl
HIPP alone. The combination treatment also resulted in significantly increased apoptosis of tumor
cells as measured by increase in % of cleaved caspase-3 positive cells. Additionally, the TIC
marker CD133 was drastically downregulated upon combination treatment. However, the
combination treatment did not prolong the survival of the mice (Figure 1-10).
For the first time, we have identified a possible role of CtBP2 in PDAC growth and
metastasis. However, the exact mechanism still requires further investigation. The study findings
open a fruitful avenue to further explore the role of CtBP2 in PDAC.
The following chapters in the dissertation are an attempt to clearly understand the role of
CtBP2 in the etiology and progression of PDAC.
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Results

Figure 1-8: Expression and role of CtBP in human and murine PDAC tumor progression.
A, B Allred score distribution for CtBP1 (a) and CtBP2 (b) in PDAC tumor specimens obtained
from PDAC patients across TNM stages I–IV and stained for CtBP1 and 2 by IHC. C Kaplan–
Meier survival curves for CKP and CKP2 mice, n = 15/group; median survivals were 8.1 and 9.5
weeks, respectively; p < 0.001. D Box plot of tumor weights obtained from CKP and CKP2
mice, n = 10/group;

*p < 0.001.

(inset)

Representative

images

of

CKP

vs.

CKP2

tumors. E Quantitation of the number of malignant peritoneal implants in CKP and CKP2 mice at
6–8 weeks of age. F Mesentery of representative CKP and CKP2 mice. Arrows indicate peritoneal
implants in CKP mesentery (left panel), while no implants are observed in CKP2 mesentery (right
panel). G H&E section of metastatic lesion obtained from a CKP mesenteric implant; arrows
indicate pleomorphic nuclei (×400). H Quantitation of ascitic fluid volumes in each genotype;
*p < 0.02.
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Figure 1-9: Expression of pancreatic TIC markers requires physiologic levels of Ctbp2.
a Representative IHC analysis of c-Myc expression in CKP and CKP2 mouse pancreatic tumors;
the dashed line divides the area of normal acini (N) from tumor (T). b Representative IHC analysis
of cancer stem cell markers CD44 and CD133 in CKP and CKP2 mouse pancreatic tumors.
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Figure 1-10: Combination therapy with CtBP2 inhibitor induces apoptosis and significantly
reduces pancreatic tumor burden. A. Schema for treatment of CKP mice with vehicle,
gemcitabine, 4-Cl-HIPP, or the combination, 3× per week for 3 weeks or until humane
endpoint. b Representative images of tumors obtained from CKP mice treated with vehicle,
gemcitabine, 4-Cl-HIPP, or gemcitabine and 4-Cl-HIPP. c Quantification of tumor weights
obtained from mice treated with above-listed drugs, n = 5 mice/treatment group. d Quantification
of

ascites

aspirated

from

CKP

mice

treated

with

above-mentioned

drugs, n = 5

mice/group. e, f Representative IHC staining of pancreatic tumors for TIC marker CD133 (e) and
apoptosis indicator cleaved caspase 3 (f) obtained from CKP mice treated with above-mentioned
drugs. Methods: CKP mice were injected with vehicle, gemcitabine (10 mg/kg, IP), 4-Cl-HIPP
(100 mg/kg, IP) or a combination of both, intraperitoneally three times a week for 3 weeks, or until
humane endpoint. At killing, tumor weights and ascites were measured.
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2

2.1

Chapter 2: Oncogenic role of CtBP2 in PDAC growth and metastasis

Abstract

The transcriptional coregulator CtBP2 has been implicated as an oncogene in colon, prostate,
breast and ovarian cancers. Previously, we reported overexpression of CtBP2 in human PDAC
specimens. However, its exact role in PDAC is still unclear. In the current study, we attempt to
delineate the oncogenic role CtBP2 in PDAC growth and metastasis. Using an orthotopic
syngeneic pancreatic tumor mouse model (CKP), we found that deletion of Ctbp2 decreases PDAC
tumor growth, proliferation, metastasis, EMT and significantly prolongs survival. Further, we
identified significant downregulation of Erbb3 mRNA levels upon deletion of Ctbp2 in CKP
PDAC cells As ErbB3 signaling was previously reported to play a critical role in pancreatic
tumorigenesis, we hypothesized that CtBP2 regulation of ErbB3 signaling at least, in part,
contributes to PDAC growth and metastasis. Upon mechanistic exploration, we found that CtBP2
interactor and Erbb3 regulator, Znp217, was concomitantly downregulated upon deletion of
Ctbp2. On the other hand, tumors obtained from Ctbp2 KO cohort showed a significant increase
in E-cadherin levels, recalling previous findings in breast cancer, and suggesting a possible role of
CtBP2 in epithelial-mesenchymal transition (EMT) in PDAC cells. In addition, in vitro tumor cell
migration assays showed decreased CKP cell migration upon deletion of Ctbp2. Our findings
establish a dual oncogenic role of CtBP2 in PDAC growth, including through ErbB3/PI3K
regulation as well as EMT/metastasis via regulation of E-cadherin/PI3K signaling. In vitro studies
demonstrated increased cytotoxicity upon combining CtBP2 chemical inhibitors with ErbB3/PI3K
inhibitors. Our findings suggest new avenues to test CtBP2 inhibitors in combination with effective
ErbB3 or PI3K inhibitors as a novel treatment strategy to tackle metastatic PDAC.
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2.2

Introduction

C-terminal binding proteins (CtBP) 1 and 2 were identified as evolutionarily conserved
transcriptional coregulators that alter gene expression by interacting with other DNA binding
transcriptional factors (Chinnadurai, 2002). CtBP 1 and 2 were reported to be overexpressed in
colon, breast, ovarian, prostate, and gastric cancers, and frequently associated with poor patient
outcomes (Barroilhet et al., 2013a; Y Deng et al., 2010; Straza et al., 2010; R. Wang et al., 2012).
Mechanistic studies revealed CtBPs promote repression of tumor suppressor genes like BIK (Kovi
et al., 2010), BRCA1 (Yu Deng et al., 2012), PTEN , and E-cadherin (Deng et al., 2012) to
ultimately promote tumor growth, proliferation and epithelial-mesenchymal transition (EMT) in
various cancers. In addition, CtBP2 overexpression promotes tumor cell migration via
transcriptional activation of TIAM-1 gene expression and CtBP2 was shown to promote cancer
stem cell growth and self-renewal by upregulating TCF4 (Transcriptional Factor 4) signaling
(Patel et al., 2014b). Interestingly, chemical inhibition of CtBP2 activity was found to be beneficial
in targeting cancer stem cells (A. T. Chawla et al., 2018).
Previously, we documented the role of CtBP2 in Apc mutated neoplasia, where loss of an
allele of Ctbp2 resulted in decreased polyposis and prolonged survival of Apcmin mice (E. T.
Sumner et al., 2017). The effect was mainly attributed to decreased beta-catenin and cyclin D1
levels with allelic loss of Ctbp2. Further, CtBP was reported as a critical regulator for tumor
initiating cell (TIC) activity in Apc mutated neoplasia (A. T. Chawla et al., 2018). The effects of
allelic loss of Ctbp2 were mimicked using chemical inhibitors, which were reported as anti-cancer
agents providing therapeutic advantage (Korwar et al., 2016). Overall, the findings so far
demonstrate the multiple oncogenic roles exerted by CtBP 1 and 2 in various cancers. However,
it’s putative oncogenic role in PDAC growth and metastasis is unclear.
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PDAC which constitutes the majority of pancreatic cancers, remains to be one of the most
lethal cancers, with a five-year survival rate of less than 10% (Adel, 2019). Only limited success
is observed with existing therapies, mainly due to the complex nature of disease progression. The
presence of tumor metastasis at the time of diagnosis is one of the major limitations in developing
curative therapies for PDAC. There is thus an immediate need to fully understand the underlying
pathogenesis of PDAC tumor progression, so that novel therapies can be developed that can
effectively target PDAC or prevent its progression from precursor lesions.
In the current study, we attempt to uncover the role of CtBP2 in PDAC growth and
metastasis/EMT, and identify translational possibilities to develop CtBP2 inhibitors either alone,
or in combination with other drugs, as novel treatment strategies for pancreatic cancer. The
rationale for the current study is the recent finding that loss of an allele of Ctbp2 decreased
metastatic tumor burden and prolonged the survival of CKP mice with PDAC tumors (A. T.
Chawla et al., 2019). In addition, we also observed a drastic reduction in oncoprotein c-Myc levels
and tumor initiating marker (TIC) CD133 upon deletion of Ctbp2. Though the decreased levels of
CD133 and c-Myc may account for the observed decreased metastasis of PDAC in the setting of
Ctbp2 deficiency, the role of CtBP2 in PDAC growth and metastasis is still unclear (A. T. Chawla
et al., 2019).
In this work, we studied the impact of Ctbp2 deletion on PDAC growth and
metastasis/EMT, using an orthotopic syngeneic pancreatic tumor mouse model. As speculated,
deletion of Ctbp2 resulted in decreased pancreatic tumor growth rate, proliferation, metastasis and
EMT, with significantly prolonged survival. Interestingly, we identified for the first time that
Ctbp2 regulates Erbb3 signaling via an interacting partner Znp217 in PDAC. In addition, we also
found that deletion of Ctbp2 increased E-cadherin levels, correlating with previous findings (M
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Grooteclaes et al., 2003) . Our work established multiple oncogenic roles of CtBP2 in PDAC
growth, metastasis, and EMT possibly via regulation of ErbB3/PI3K signaling. Based on the
findings, we identified dual inhibition of CtBP2 and PI3K as an attractive strategy to treat highly
metastatic PDAC.

2.3

Materials and Methods

2.3.1 Mouse Models and Animal Treatments
Four-month-old NSG mice procured from Virginia Commonwealth University Cancer Mouse
Models Core Laboratory were used for the study. The study protocols were approved by the
Institutional Animal Care and Use Committee of Virginia Commonwealth University. For the drug
testing studies, we orthotopically injected approximately 0.5x106 CKP (Chai et al., 2013) cells into
pancreatic tail vein of mice, and post one week of injection, animals were randomized into four
groups, where each group (n=3/group) received either Vehicle or Erlotinib (50mg/Kg) or 4-Cl
HIPP (100mg/Kg) or Combination (Erlotinib (50mg/Kg) and 4-Cl HIPP (100mg/Kg)) treatment
every other day for three weeks. After the treatment, animals were euthanized and pancreatic
tumors were isolated.

2.3.2 Generation of CKP mouse PDAC cell line
The mouse CKP PDAC cell line was developed from the pancreas of a two-month-old CKP (Pdx1Cre.LSL.Kras

G12D

p53flox/flox) mouse generated by the VCU Transgenic/Knockout Core as

described by (Torres et al., 2013). The CKP cell line was characterized for PDAC markers Ck19
and Muc4 by qPCR. The cells were tested for mycoplasma by qPCR using routine procedures. We
employed CRISPR-Cas9 gene editing technology to knock out CtBP2, and the resulting clones
were validated for deletion of CtBP2 by immunoblotting. We selected one of the several clones
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generated, referred to as CKP CtBP2 KO and used for all the experiments. These cell lines were
grown in monolayers using RPMI media (Life Technologies) supplemented with 4% FBS and 1%
penicillin and streptomycin. Cells were grown at 37°C in 5% CO2 and passaged when confluent
for the experiments.

2.3.3 Retroviral mediated transfection
The lentiviral vector pFULT expressing luciferase linked to Tomato under the control of the human
pPGK1 promoter, was purchased from Northwestern University. CKP and CKP CtBP2 KO cells
were infected with virus and 24hrs later, the media in the cell culture dish was replaced with fresh
media. After 24hrs, we started the selection process by treatment with puromycin (1.25µg/ml) for
7 days, after which we performed an in vitro luciferase assay to confirm luciferase expression. All
cells in the control plate died due to puromycin treatment.

2.3.4 Measurement of Luciferase activity
CKP and CKP CtBP2 KO cell lines were seeded as 100K, 75K, 50K, 25K, or 12.5K cells/well in
triplicate in a 96 well plate. An equal volume of D-luciferin was added to each well (30 µg/ml)
and incubated for 5, 8, or 10 mins, following which bioluminescence was measured using the IVIS
100 instrument. Stable luciferase expression was confirmed by performing the assay after three
months of maintenance of cells in the culture. Also, stable luciferase expression was confirmed by
immunoblotting using luciferase antibody.
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2.3.5 Orthotopic injection of CKP cells and Bioluminescence imaging (BLI)
We injected approximately 8x105 luciferase expressing CKP and CKP CtBP2 KO cells in PBS
mixed with an equal volume of Cultrex Basement Membrane Matrix, type 3 on ice into the
pancreatic tail vein of mice. The procedure was performed as described by (Chai et al., 2013). The
procedure was approved by the Institutional Animal Care and Use Committee of Virginia
Commonwealth University. The adherence of the cells to the pancreas was measured by
subcutaneous injection of D-luciferin (150mg/kg), and bioluminescence was measured 10 mins
post injection using IVIS 100. Tumor growth was monitored via weekly imaging using IVIS 100
(n=5/group).

2.3.6 Trans-well Migration Assay
Approximately, 4x104 cells of CKP and CKP CtBP2 KO cells were seeded in serum free RPMI
media on a trans-well migration insert (Corning® Transwell® polycarbonate membrane cell culture
inserts- Cat. No. 3428) placed in a six well culture plate. The inserts were incubated with regular
media overnight for better adherence of the cells as specified by the manufacturer, before addition
of cell suspension to the inserts. The bottom of the well contained regular RPMI media with 10 %
FBS that acts as chemoattractant for the migration of cells. After 24hrs, the media from the wells
were aspirated and cells were washed with cold PBS. Later, cells were stained using 0.5 % (w/v)
crystal violet solution in 20% methanol. The percentage of cells migrated were analyzed by
counting the number of cells stained with crystal violet manually on the trans-well migration
membrane using a light microscope at 40X from five random fields.
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2.3.7 Cell Viability assays
To measure sensitivity of CKP and CKP CtBP2 KO cell lines to CtBP2, ErbB3 and PI3K inhibitors
cells were trypsinized and mixed with trypan blue and counted using an automatic cell counter
with hemocytometer. Approximately, 5000 cells of each cell line were seeded in a 96 well plate
and incubated for 4hrs at 37°C. Once the cell adherence was confirmed using a light microscope,
cells were treated with CtBP2 inhibitor (4-chloro-2-hydroxy-imino-phenyl-pyruvate; 2mM-0mM),
ErbB3 inhibitor (erlotinib; 100µM-0µM), PI3K inhibitor (LY 294002; 10µM-0µM) and incubated
at 37°C for 72hrs. To measure the extent of cell viability post-treatment, cells were fixed using
100% methanol for 20 min at -20°C and each well was stained by addition of 50µl of 0.5 % (w/v)
crystal violet in 20% methanol to each well and incubated for 20min at room temperature on a
rocker. The stained plates were washed in distilled water to remove the unstained cells and air
dried overnight. The next day, the crystal violet stain was dissolved by addition of 10% glacial
acetic acid to each well, followed by incubation at room temperature for 20 mins on a rocker.
Absorbance was measured at 570nm using a plate reader (Syngene). The percentage cell viability
was calculated by recording the absorbance of the vehicle treated wells as 100%.

2.3.8 Immunoblotting
Tumor Tissues: After isolation, tumor tissues were powdered in liquid nitrogen using a mortar
and pestle. RIPA (1X) buffer, containing freshly prepared protease and phosphatase inhibitors was
added to the powdered tissue and incubated on ice for 10 min.
Adherent Cells: Cells were initially washed with ice-cold PBS (1X), scrapped on ice and pelleted
by cold centrifugation at 8000 rpm for 5min at 4°C. The cell pellet was lysed using cold 1X RIPA
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buffer (Cell Signaling Technology) containing protease (Mini EDTA tablet) and phosphatase
inhibitors (Roche) freshly added on ice and incubated for10 min.
The supernatant cell/tissue lysate was collected after centrifugation of lysed cells/tissues at 12000
rpm for 10min at 4°C. The protein concentration in the lysate was measured using BCA reagent
(Pierce BCA kit). 30µg of total protein mixed with LDS buffer (1x) and heated in a sand bath for
10 min at 95°C was loaded onto a 4-12% Bis-Tris gel (Novus gels) or 3-6% Tris-acetate gels and
electrophoresis was performed at 200V/40min or 140V/70mins respectively, using running buffer
(MOPS/SDS (1X) or Tris-acetate (1X)). Separated proteins were transferred to a 0.45µm
nitrocellulose membrane using Tris-glycine transfer buffer containing 20% methanol.
Nitrocellulose membranes were later blocked using LiCoR blocking buffer or 5% Milk in
TBST(1X) for 1h at room temperature, after which they were incubated with primary antibodies.
CtBP2 (BD Biosciences, 1:1000, Cat. No:612044), GAPDH (Millipore, 1:20000, Cat No: AB
2302), Luciferase (Santa Cruz biotechnology, 1:3000, Cat No SC 74548), ErbB3 (Cell Signaling
Technology, 1:1000, Cat No:12708), E-cadherin (Cell Signaling Technology, 1:1000, Cat No:
3195) primary antibodies were prepared in blocking buffer containing 0.1% Tween 20, and
incubated with membranes overnight at 4°C on the rocker. Following three washes (10 min each
wash on the rocker) with (1X) PBST, the membranes were incubated with fluorophore tagged
secondary antibodies (anti-rabbit and anti-mouse) (Thermofisher) with dilution ratio 1:10000 in
blocking buffer. Membranes were washed three times in PBST(1X) and protein bands were
detected using LI-COR.
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2.3.9 Immunohistochemistry
Paraffin embedded tissue sections were deparaffinized by washing the slides in Citra solv and then
hydrated by washing in a series of graded alcohols. Following which, antigen unmasking by heat
treatment was performed by placing the tissue sections in retrieving solution (BD Pharmingen
Retrievagen A, pH 6.0) using antigen Retriever 2100 as per manufacturer instructions. Slides were
later incubated in 3% peroxidase to quench endogenous peroxidase activity and tissue sections
were circled using a hydrophobic PAP pen marker. After a washing step, the slides were incubated
in blocking buffer (0.1% BSA in 5% Goat serum or in 0.1% PBST) for 1hr at room temperature.
After a five-minute wash three times with PBST, the slides were incubated with the following
primary antibodies: CtBP2 (Santacruz, Goat 1: 100 Cat No: SC 5966), ErbB3 (Cell Signaling
Technology, 1:200, Cat No:12708), E-cadherin (Cell Signaling Technology, 1:200, Cat No: 3195),
PTEN (CST, 1:200, Cat No: 9559) , Ki67 (Millipore, 1:200 Cat No: AB 9260) overnight at 4°C.
After a series of washes in PBST(1X), slides were incubated with HRP tagged secondary
antibodies (rabbit and mouse Jackson Labs; dilution ratio 1:500) for 1h at room temperature. After
a few washing steps, the slides were DAB stained (DAKO Chromogen) and counter stained using
Mayer’s Hematoxylin for 5 mins. Finally, slides were dehydrated by washing through graded
alcohols and Citra Solv. In the final step, the slides were cover slipped by adding a drop of
mounting media (Permount).

2.3.10 RNA Sequencing
Quickly after euthanizing the mice, pancreata were harvested under ice-cold conditions. The
isolated tissues were powdered by triturating using liquid nitrogen, and RNA was extracted by
performing Triazole-Chloroform extraction method. Total RNA was isolated using RNeasy Mini
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kit (Qiagen) according to the manufacturer’s recommendations. RNA integrity number (RIN)
value was assessed on an Agilent 2100 Bioanalyzer, and samples with RIN value above 9 were
selected for sequencing purposes. Prior to the RNA-Seq, ribosomal RNA was depleted from the
samples using the RiboMinusTM Human/Mouse Transcriptome Isolation Kit (Thermo Fisher
Scientific, Waltham, MA). All samples were sequenced on the Illumina Hi-Seq sequencer; ~29
million 50 bp single-end reads per sample were obtained. Sequencing adapters were removed using
Trimmomatic v.0.33 (Bolger et al., 2014) . Quality control at each processing step was performed
using the FastQC tool v0.11.2 (quality base calls, CG content distribution, duplicate levels,
complexity level). The Mouse GRCm38/mm10 reference genome was obtained from UCSC
Genome

Browser

Gateway

(http://hgdownload.soe.ucsc.edu/goldenPath/mm10/bigZips/chromFa.tar.gz),
corresponding

gene

annotation

(ftp://ftp.ensembl.org/pub/release-83/

file

was

obtained

and
from

the
Ensemble

gtf/mus_musculus/Mus_musculus.GRCm38.83.gtf.gz).

Only autosomes, mitochondrial, and sex chromosomes were used. Reads were aligned using the
subread v.1.6.2 aligne. We obtained gene counts for each sample based on the last hg38 version of
Ensembl transcriptome (v.87) using the featureCounts v.1.2.6 software (Liao et al., 2014) . RNAseq counts were preprocessed and analyzed for differential expression using edgeR v.3.24.3
(Robinson et al., 2010). p-values for differentially expressed genes were corrected using a False
Discovery Rate (FDR) multiple testing correction method (Benjamini & Hochberg, 1995).
Functional enrichment analysis (GO, KEGG) was performed using enrichr (E. Y. Chen et al.,
2013). Enrichment analysis using custom signatures was performed using a hypergeometric test in
the clusterProfiler v.3.10.1 R package (Yu et al., 2012). Row-median centered log2(T P M + 1)
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expression profiles for selected genes were visualized using the pheatmap package v.1.0.12. All
statistical calculations were performed within R/Bioconductor environment v3.5.3.

2.3.11 Quantitative Polymerase Chain Reaction (qPCR)
The cDNA from the extracted RNA was prepared using SensiFAST cDNA Synthesis Kit – Bioline
by PCR as per the manufacturer specifications. The mouse qPCR primers were designed using
PrimerBank (https://pga.mgh.harvard.edu/primerbank/) and validated using the NCBI BLAST
program. RT-PCR (Real Time- Polymerase Chain Reaction) was carried out using SYBR Green
probes. Relative mRNA expression was calculated by 2-ΔΔCt method using 18S RNA as internal
standard.
The following mouse primer pairs were used.
18S: Forward primer: 5’-GTAACCCGTTGAACCCCATT 3’
Reverse primer: 3’CCATCCAATCGGTAGTAGCG5’
Erbb3: Forward primer 5’AAGTGACAGGCTATGTACTGGT3’
Reverse primer 3’AAGTGACAGGCTATGTACTGGT5’
Ctbp2: Forward primer 5’GGGATAGAACGATCTCTGGGC3’
Reverse primer 3’AGTGCAAGGAGACGCAGTC5’
Znp217 Forward primer: 5’CTTCCCAAATAAGCAGAGCCTC3’
Reverse primer 3’GGGTTCCTCTCGGTGGTCA5’
2.3.12 Statistical Analysis
All the data shown was analyzed using GraphPad Prism 8.4.1 and data is represented as mean
±SEM. Paired t-test was performed to find significant differences between two groups and p-value
was reported. p<0.05 was reported to be a significant difference between groups.
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2.4

Results

2.4.1 Generation of a bioluminescent mouse CKP PDAC cell line
CKP mice were generated and genotyped by the VCU Transgenic/Knockout Core based on a
previous report (Bardeesy et al., 2006). CKP mice develop adenocarcinoma rapidly, with a median
survival of 8.8 weeks (A. T. Chawla et al., 2019). A CKP cell line was derived from CKP tumors
as shown in (Figure 2-1A) (Torres et al., 2013). The cell line was characterized for PDAC markers,
including CK-19 and Muc4, by qPCR as described (Torres et al., 2013) and higher mRNA levels
of CK19 and Muc4 were observed in the cell line when compared to levels in normal mouse
pancreas (Supplemental Figure S1-1). The phenotype of CKP mice closely mimic the clinical
course of the majority of human PDAC patients bearing an oncogenic KRAS mutation and
mutated/inactivated TP53 (Güngör et al., 2014). We next used CRISPR-Cas9 technology to knock
out CtBP2 in the CKP cell line, which was confirmed by western blotting (Figure 2-1B). Both
CKP and CKP CtBP2 KO cell lines were later transfected using a retroviral vector containing the
pPGK1 promoter driving a luciferase reporter. Luciferase expression in both cell lines was
confirmed by in vitro luciferase assay (Figure 2-1C and 2-1D). Both cell lines maintained equal
and stable luciferase expression even after 3 months in culture. This was additionally confirmed
by immunoblotting for luciferase protein in both CKP and CKP CtBP2 KO cell lysates. Equal
luciferase protein abundance was detected in both cell lines (Supplemental Figure S1-2).
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Figure 2-1: Generation of CKP-luciferase cell line. A) Isolation of primary pancreatic tumors from
CKP mice, collagenase digestion and isolation of tumor cells to develop CKP cell line. B) CtBP2
deletion was confirmed by Western blot. C) Luciferase expression of CKP and CKP CtBP2 KO
cells and D) Invitro luciferase assay (n=2, no significant difference in the luciferase activity
between two cell lines).
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2.4.2 Loss of CtBP2 delays PDAC growth and prolongs survival
To understand the putative role of CtBP2 in PDAC, CKP and CKP CtBP2 KO luciferase
expressing cell lines were injected orthotopically into the pancreatic tail vein of four-month-old
NSG (n=5/group) mice, a model to negate the impact of immune system and focus on the
autonomous effects of CtBP2 The adherence of the cells was confirmed by IVIS imaging (Figure
2-2A). Tumor growth rate was measured by weekly IVIS imaging (Figure 2-2B) and the total
photon flux signal was quantified using “Living Image” software (Figure 2-2C). Mice carrying
CKP tumors showed a significant increase in tumor growth rate when compared to the CKP CtBP2
KO cohort. Three weeks after injection, upon on isolation of the pancreas, the average weight of
pancreata from the CKP cohort was an average of two-fold higher than the CKP CtBP2 KO group
(Figure 2-2D). Further, we found an increased accumulation of ascitic fluid in the CKP mice,
when compared to CKP CtBP2 KO mice (Figure 2-2E). Of note, accumulation of ascitic fluid is
a clear indicator of metastatic disease progression in human PDAC patients (Sangisetty & Miner,
2012)

Upon survival to the humane end point, mice implanted with CKP CtBP2 KO cells survived
significantly longer than mice in the CKP group. The median survival of CKP group mice was 3
weeks post injections, while mice implanted with CKP CtBP2 KO cells survived for 4.4 weeks
(Figure 2-2F). This result was in concordance with our previous findings, in which deletion of an
allele of Ctbp2 prolonged the survival of mice with mutated Apc and CKP mice with PDAC tumors
(A. T. Chawla et al., 2019; Evan T. Sumner, 2016). When the body weight of the mice was
measured weekly, we found a significant increase in the body weight of the mice which were
injected with CKP tumor cells as compared to CKP CtBP2 KO tumor cells (Supplemental Figure
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S1-3) mainly due to the accumulation of ascitic fluid. The findings suggested that CtBP2 might be
crucial for PDAC growth and metastasis.
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Figure 2-2: Deletion of CtBP2 delays growth of PDAC and prolongs survival. (A) Schema of
the study. (B) Bioluminescent images at indicated days after injection of luciferase expressing
CKP vs. CKP CtBP2 KO cells. (C) Quantification of total photon flux per second representing
the rate of tumor growth in mice injected with CKP or CKP CtBP2 KO cells. (D) Effect of
CtBP2 deletion on tumor weight. (E) Effect of CtBP2 deletion on accumulation of ascitic fluid.
(F) Kaplan-Meier analysis of CKP and CKP CtBP2 KO injected mice post injection of cells,
with median survival 3 weeks and 4.4 weeks post injection of cells (n=4/group) Log-rank
(Mantel-Cox) test indicated p < 0.05 for survival comparison between two groups in (F). p values
were obtained by performing paired t-test between the two groups (n=5/group). * or ***
indicates p<0.05. Error bars indicate S.E.M.
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2.4.3 Loss of CtBP2 decreases PDAC tumor cell proliferation
As we observed an increased tumor growth rate of CKP cells when compared to CKP CtBP2 KO,
we next sought to probe for cell proliferation markers. CtBP2 was previously shown to repress cell
cycle regulator p16INK4A to promote malignant growth of squamous cell carcinoma (Guan et al.,
2013). We performed immunohistochemical staining of primary pancreatic tumor sections from
both the cohorts (CKP and CKP CtBP2 KO) for the Ki67 a cell proliferation marker. Staining
intensity was scored on a scale of 0-3, with 0: No staining, 1: weak staining, 2: moderate staining
and 3: intense staining. Interestingly, we found that pancreatic tumor sections from the CKP cohort
showed abundant levels of Ki67, when compared to the CKP CtBP2 KO group, which exhibited
much lower, barely detectable, levels (Figure 2-3A-B). The results signify possible cell cycle
regulation by CtBP2 in PDAC, which requires further investigation.

Figure 2-3: Effect of CtBP2 loss on PDAC cell proliferation. (A) Representative primary
pancreatic tumor sections from CKP and CKP CtBP2 KO cohorts immunohistochemically
stained with Ki67, a cell proliferation marker. (B) Quantification of IHC staining based on the
intensity of staining (n=5/group). p values were obtained by performing paired t-test between
the two groups. p<0.05. Error bars indicate S.E.M. Scale bar 50µm.
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2.4.4 Regulation of EMT, metastasis and tumor cell migration by CtBP2
Since CtBP2 was previously shown to promote EMT by transcriptional repression of E-cadherin,
we checked the effect of CtBP2 deletion on markers of EMT, including E-cadherin and vimentin,
in the orthotopic mouse PDAC model (Yu Deng et al., 2012). E-cadherin levels were significantly
upregulated in primary pancreatic tumor sections from the CKP CtBP2 KO group when compared
to tumor sections from the CKP group (Figure 2-4A & 2-4C). On the contrary, vimentin, a
mesenchymal EMT marker, was found to be highly expressed in CKP tumors when compared to
CKP CtBP2 KO tumors (Figure 2-4A & 2-4B). Abundant expression of vimentin is indicative of
tumor cells losing their epithelial nature, and acquiring an invasive mesenchymal nature, a feature
of EMT (Kalluri & Weinberg, 2009).
Since, EMT has been shown to be associated with metastasis, and PDAC is characterized by
abundant metastatic potential, we investigated the role of CtBP2 in the metastasis of PDAC in the
orthotopic mouse model (Pastushenko et al., 2018; Sahin et al., 2018). At week 3 after orthotopic
injection of cells, the group which received CKP cells showed extensive tumor metastasis to
different organs (~100% mice) when compared to the CKP CtBP2 KO group (~20% mice) (Table
2). In mice carrying CKP cells, secondary tumors were found in various organs like kidneys,
spleen, liver and intestines (Figure 2-4D &E). This finding correlated with our previous report, in
which we demonstrated deletion of an allele of Ctbp2 decreased metastatic tumor burden to the
peritoneum in CKP mice with PDAC (A. T. Chawla et al., 2019).
We further confirmed our in vivo findings by performing an in vitro trans-well migration assay
using CKP and CKP CtBP2 KO cells, and found a significant decrease in the number of CKP
CtBP2 KO cells migrated when compared with CKP (Figure 2-4F). These results reveal new
insights into CtBP2’s role in regulation of EMT, metastasis and tumor cell migration in PDAC.
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Table 2:Percentage of mice in each cohort that showed tumors in various organs.
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Figure 2-4: CtBP2 promotes EMT and metastasis: (A) Representative pancreatic tumor sections
stained with E-cadherin and vimentin. (B) Vimentin staining based on staining intensity (scale
0-3) (n=3/group), p < 0.05. (C) E-cadherin staining based on staining intensity (0-3)
(n=4/group), p < 0.05. (D) Representative H&E staining of tissue from various organs of NSG
mice orthotopically injected with CKP and CKP CtBP2 KO cells. Blue arrows indicate
metastatic tumors. Scale bars: 100μm. (E) Metastatic tumor sites observed in various organs of
mouse that received CKP tumors (L:Liver; I:Intestines: S:Spleen; K:Kidneys) (F) Average
number of cells migrated per field from five random fields of trans-well membrane upon staining
with crystal violet (n=3), p < 0.05. p values were obtained by performing paired t-test between
the two groups. Error bars indicate S.E.M. Scale bar 50µm.
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2.4.5 Deletion of CtBP2 alters ErbB3/PI3K signaling pathway
We next sought to determine the changes in gene expression between the CKP and CKP CtBP2KO
groups. Total RNA was extracted from 5 freshly isolated pancreatic tumors from each of CKP and
CKP CtBP2 KO group. We performed RNA sequencing analysis and compared differentially
expressed genes between the CKP and CKP CtBP2 KO cohorts (n=5/group) at False Discovery
rate (FDR) 0.01 (Figure 2-5A). A total of 782 protein coding genes are altered upon deletion of
CtBP2
Of the top fifty genes that were differentially expressed between the two groups, of major
interest was the oncogene Erbb3, a member of the EGFR family that includes EGF Receptor and
ERBB2. Erbb3 was found to be significantly downregulated upon deletion of CtBP2. We further
validated results of the RNA sequencing analysis by performing a qPCR (Figure 2-5B). The
mRNA levels of Erbb3 were significantly downregulated in CKP CtBP2 KO tumors when
compared to CKP tumors. ErBB3 was earlier shown to be regulated by the transcription factor
ZNF217 upon interaction with CtBP2 (Krig et al., 2010). We next determined the mRNA level of
mouse Znp217, and interestingly, deletion of CtBP2 caused transcriptional downregulation of both
Erbb3 and Znp217 (Figure 2-5B). From these results, we were able to speculate that CtBP2
regulates Erbb3 gene expression by interacting with Znp217 to possibly contribute to PDAC
growth and metastasis.
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A.
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B.

Figure 2-5: CtBP2 deletion alters Erbb3 gene expression. (A) Heatmap showing top 50
differentially regulated genes between the CKP and CKP CtBP2KO tumors from NSG mice
three weeks after orthotopic injection of cells (n=5/group). (B) Validation of RNA seq results
by qPCR. Relative mRNA levels of indicated genes measured using SYBR Green probe by 2ΔΔCt

method using RT-PCR (n=3 independent biological replicates/ group). p values were

obtained by performing paired t-test between the two groups. p<0.05 was considered to be
significantly different. Error bars indicate S.E.M.
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2.4.6 CtBP2 regulates ErbB3/PI3K signaling
We next interrogated the changes in protein levels of ErbB3 upon deletion of CtBP2.
Immunoblotting lysates of pancreatic tumors harvested from both CKP and CKP CtBP2 KO
cohorts revealed a significant decrease in ErbB3 protein levels upon deletion of CtBP2 (Figure 26A&B).
Phospho-Inositol-3 Kinase (PI3K), a downstream effector of ErbB3 signaling, was earlier
reported to be activated upon over expression of CtBP2 in lung carcinoma cells (Seema Paliwal et
al., 2007). Indeed, we found a drastic reduction in phospho-PI3K levels in lysates of CKP CtBP
KO cells when compared with CKP cells (Figure 2-6C; left panel). In parallel, we validated our
study results using a colorectal tumor cell line HCT116 with mutant K-RAS, as positive control
which expresses phospho-PI3Kinase. Similar to CKP, we found a sharp decrease in phospho-PI3K
levels upon deletion of CtBP2 (Figure 2-6C; right panel). Altogether, our results reveal possible
regulation of phospho-PI3K signaling by CtBP2, consistent with previous report in which
overexpression of CtBP2 was associated with increased phospho-PI3K signaling (Seema Paliwal
et al., 2007).
In an attempt to find any correlation that exists between the ErbB3 and CtBP2 expression
in human PDAC patients, we performed a correlational analysis using TCGA human PDAC
specimen data for mRNA expression of ErbB3 and CtBP2 in human PDAC specimens, and found
that ErbB3 and CtBP2 expression levels are significantly positively correlated (Figure 2-6D).
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Figure 2-6: CtBP2 deletion downregulates Erbb3 gene expression.

58

Chougoni 2020

(A) Immunoblotting of indicated proteins in pancreatic tumor lysates from mice orthotopically
implanted with CKP and CKP CtBP2 KO cells (three independent mice per group). (B)
Quantification of band intensities from immunoblot in (A) using ImageJ software. (C) Western
blotting of CKP, CKP CtBP2 KO, HCT116 and HCT 116 CtBP2 KO cell lysates for CtBP2 and
phospho-PI3K. p values were obtained by performing paired t-test between the two groups.
p<0.05 was considered to be significantly different. Error bars indicate S.E.M. (D) Correlational
analysis of CtBP2 and ErbB3 expression in human PDAC specimens from TCGA was
performed using “R2: Genomics Analysis and Visualization platform” (http://r2.amc.nl
http://r2platform.com). CtBP2 and ErbB3 were found to be positively correlated with p value
<0.05.

2.4.7 In-vitro and In-vivo testing of combined inhibition of CtBP2 and ErbB3/PI3K
Based on our findings, we reasoned that dual inhibition of CtBP2 and ErbB3/PI3K signaling might
be an effective strategy to target PDAC cells. In-vitro cytotoxicity assays were performed by
treating both CKP and CKP CtBP2 KO cell lines with CtBP2 inhibitor (4-Cl HIPP), ErbB3
inhibitor (Erlotinib) or PI3K inhibitor (LY294002) for 72hrs. Both CKP and CKP CtBP2 KO cell
lines were resistant to most of the chemical inhibitors. At the 72hrs time point, IC50 values were
as shown in Table 2 (Figure 2-7A-D). However, no statistically significant difference was
observed in response to various treatments between the CKP and CKP CtBP2 KO cells. To
potentiate cell killing, we combined 4-Cl HIPP and Erlotinib, and treated the cells for 72hrs.
Remarkably, we observed reduction of the IC50 values of both CKP and CKP CtBP2 KO cells
(Table 2). Especially, CKP CtBP2 KO cells were very sensitive to the combination of erlotinib
and 4-Cl HIPP. This combination could be useful in reducing the adverse effects associated with
high doses of erlotinib, but at the same time improving cytotoxicity. Both CKP and CKP CtBP2
KO cell lines also showed significant sensitivity to PI3K inhibitor LY294002 with an IC50 value
approximately ~13.43 and 13.24 µM respectively at 72hrs. However, upon combination with 4-Cl
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HIPP, the IC50 value of CKP CtBP2 KO for LY294002 was reduced to 0.043µM and to 326µM
for 4-Cl HIPP at 72hrs (Figure 2-7D-E). These findings emphasize the importance of CtBP2
inhibition/deletion in targeting PDAC.
We further tested the combination 4-Cl HIPP and Erlotinib using an orthotopic mouse tumor
model. We injected approximately 5x105 CKP-luciferase expressing cells orthotopically into the
pancreas of C57BL/6 wild type mice. Later, these animals were randomized into four groups and
treated with vehicle, erlotinib (50mg/Kg), 4-Cl HIPP (100mg/Kg), or the combination (erlotinib +
4-Cl HIPP) (n=3/group) every other day for two weeks. We observed that mice which received the
combination treatment did not show any decrease in weight of pancreas or metastasis, when
compared to either vehicle, Erlotinib or 4-Cl HIPP treatment (Figure 2-7F). However, the mice
treated with the combination were healthy, while mice in other treatment groups exhibited
morbidities, such as accumulation of ascitic fluid and slowed movements, at the end of two weeks.
Of note- pancreas weight is only an indirect measure of tumor weight or volume, and further
analysis is required via histologic analysis to determine if there was a difference in effect on tumor
distribution or extent in the pancreas by any of the treatments.
Table 3 : List of IC50 values of various drugs alone or in combination
Drug (IC50)
4-Cl HIPP (mM)
Erlotinib (µM)
LY294002 (µM)

CKP
2.093
65.98
13.43

CKP CtBP2 KO
1.676
45.55
13.24

Combination treatment
4-Cl HIPP (mM)
Erlotinib (µM)

1.581
80.82

0.3783
16.86

Combination treatment
4-Cl HIPP (mM)

2.25

0.3268
60

Chougoni 2020

LY294002 (µM)

14.57

0.043
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Figure 2-7:Effect of combined inhibition of CtBP2 and ErbB3/PI3K. Measurement of cytotoxicity
using crystal violent staining method of 4-Cl-HIPP, (B) Erlotinib, (C)4-Cl HIPP + Erlotinib, (D)
LY294002, (n=3 independent experiments, error bars represent S.E.M) (E) 4Cl HIPP + LY294002
for 72hrs.The IC50 values shown were calculated by log(inhibitor) vs normalized responsevariable slope method using GraphPad Prism 8.4.1.(F) Weight of the pancreas measured following
the indicated treatments and doses delivered IP for two weeks after orthotopic injection CKP cells
into pancreatic tail vein. (n=3 mice/group; p values were obtained by performing paired t-test
between the two groups. p<0.05 was considered to be significantly different. Error bars indicate
S.E.M, p value 0.35). ETB = erlotinib.
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2.5

Discussion

PDAC is one of the most devastating cancers, with a five year survival rate below 10%, and is
projected to become the second most frequent cause of cancer related deaths by 2030. (Adel, 2019;
Haeberle & Esposito, 2019). Current therapies for the treatment of PDAC offer only a slight
improvement in patient outcomes. PDAC is a complex in nature and multiple oncogenic factors
contribute to its growth and metastasis that are not well understood. Previously, CtBP 1 and 2 have
been implicated in various cancers like colon, ovarian and breast (A. T. Chawla et al., 2018;
Stankiewicz et al., 2014; Evan T. Sumner, 2016). In our recent work, we showed that human PDAC
patients express high levels of CtBP2 protein. Using a CKP PDAC mouse model, we showed that
loss of an allele of Ctbp2 decreases metastatic tumor burden and prolongs survival (A. T. Chawla
et al., 2019). The current study is an attempt to dissect the oncogenic role of CtBP2 in PDAC.
In this study, we report loss of CtBP2 decreases PDAC tumor growth, proliferation, EMT,
metastasis and tumor cell migration, using cell lines and an orthotopic pancreatic tumor mouse
model. Our results note multiple oncogenic activities in PDAC by CtBP2. The decrease in PDAC
tumor growth in the CKP CtBP2 KO cohort, when compared to the CKP group, as assessed by
IVIS imaging recalled a previous observation in Apc min mice (Evan T. Sumner, 2016). Based on
this finding, we sought to determine any changes in tumor cell proliferation. As speculated, we
observed a drastic reduction in levels of Ki67, which is expressed in cycling cells, upon deletion
of CtBP2. Although, CtBP2 was previously shown to repress tumor suppressor p16INK4a to
promote malignant cell proliferation, its regulation of the cell cycle in PDAC needs further
investigation (Guan et al., 2013).
CtBP1/2 were shown to promote EMT by repression of E-cadherin (Yu Deng et al., 2012; ML
Grooteclaes & Frisch, 2000). Since PDAC patients present with frequent tumor metastasis, we
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examined the effect of deletion of CtBP2 on markers of EMT and on metastasis (Keleg et al.,
2003). In accordance with previous findings, E-cadherin was upregulated upon deletion of CtBP2,
accompanied by decreased levels of the mesenchymal marker vimentin, in pancreatic tumor
sections of the CtBP2 KO vs. CtBP2 cohorts, upon immunohistochemical staining. However,
whether the observed increase in E-cadherin protein levels was mainly due to relieved
transcriptional repression due to CtBP2 loss, still requires further investigation. Since EMT is
associated with metastasis in cancer cells, we examined for changes in tumor metastasis upon
deletion of CtBP2 in the orthotopic mouse model (Pastushenko et al., 2018). Surprisingly, ~100%
of mice in the CKP cohort showed tumor metastasis in various organs, such as liver, intestine and
kidneys, while only ~20% of mice in the CtBP2 KO cohort showed metastasis in these organs. In
addition, accumulation of ascitic fluid in the mice only from the CKP but not the CtBP2 KO
cohorts is an indicator CtBP2 drives peritoneal metastasis, which is normally seen in PDAC
patients (Sangisetty & Miner, 2012).
Metastasis involves migration of tumor cells from primary site to distant organs, and CtBP2 was
shown to promote tumor cell migration by activating TIAM1 gene expression (Seema Paliwal et
al., 2012). An in-vitro trans-well migration assay revealed loss of CtBP2 decreased tumor cell
migration. However, determining if induction of tumor cell migration in PDAC is through
activation of Tiam1 would be interesting. Taken together, our findings demonstrate CtBP2 as
critical regulator of PDAC EMT and metastasis.
Interestingly, upon mechanistic exploration we discovered loss of CtBP2 significantly
downregulated Erbb3 signaling. We further validated these RNA-seq results by performing a
qPCR, which showed significantly decreased mRNA levels of Erbb3 in orthotopic pancreatic
tumors null for CtBP2. ErbB3, a member of the EGFR family of growth factor receptors, was
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previously reported to play a vital role in PDAC progression and was also considered as a potential
target for the treatment of PDAC (Hao et al., 2016). CtBP1/2 were reported to interact with
transcriptional repressor ZNF217 to regulate Erbb3 gene expression (Krig et al., 2010).
Interestingly, we found a significant decrease in mRNA levels of Znp217(ZNF217 in human) in
the CKP CtBP2 KO group. To determine the translational importance of this finding, we examined
the correlation between CtBP2 and ERBB3 expression in human PDAC specimens from TCGA,
and found that they are positively correlated. We further strengthened our findings upon probing
for phopho-PI3K protein levels in the CKP vs. CKP CtBP2 KO cell lines. As expected, we found
an abrogation of PI3K activating phosphorylation upon deletion of CtBP2. Indeed, a previous
report from our lab showed transient knockdown of CtBP2 led to decreased PI3K signaling in lung
cancer cells (Seema Paliwal et al., 2012). Thus, our findings suggest that CtBP2 regulates PDAC
growth and metastasis via transcriptional activation of Erbb3 gene expression by interaction with
transcriptional factor Znp217 (Figure2-8), but require further investigation to confirm the key role
of ErBB3.
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Figure 2-8: The proposed mechanism by which CtBP2 regulates ErbB3 signaling and possibly
PDAC growth.

Previously, CtBP2 inhibitor 4-Cl HIPP was shown to induce apoptosis in colon cancer cells (Straza
et al., 2010). Treatment of CKP mice with 4-Cl HIPP caused a decrease in tumor size and exhibited
a synergistic effect when combined with gemcitabine, a popular chemotherapeutic agent used to
treat PDAC patients (A. T. Chawla et al., 2019). Based on our observations in the current study,
we rationalized that dual inhibition of CtBP2 and ErBB3/PI3K could be a potential strategy to treat
pancreatic PDAC. In vitro cytotoxicity assays performed using the CKP and CKP CtBP2 KO cell
lines showed that the combined inhibition of CtBP2 and ErbB3 (erlotinib) did not substantially
improve cell killing. In parallel, we sought to test the combination using an orthotopic model
injected with CKP cells; but the combination showed no additive or synergistic effects on
inhibition of tumor growth. In the future, combining 4-Cl HIPP with effective ErbB3 inhibitors
could be a fruitful avenue to target PDAC. As ErBB3 activation promotes PI3K signaling, we
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tested PI3Kinase inhibitors, alone, or in combination with CtBP2 inhibitors, to treat PDAC.
Indeed, 4-Cl HIPP when combined with PI3K inhibitor (LY294002) resulted in very significantly
increased cytotoxicity of CKP and CKP CtBP2 KO cells.
Our findings open up new therapeutic opportunities for the treatment of metastatic PDAC patients
by combining CtBP2 inhibitors with ErbB3 or PI3K inhibitors.
Supplemental Figures

Figure S1 1: Characterization of PDAC markers in CKP cell line. Relative mRNA levels of Ck19
and Muc4 measured using SYBR Green probe by 2-ΔΔCt method using RT-PCR (n=2 biological
replicates/ group).
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Figure S1 2: Luciferase expression in CKP cells. Western blotting of CKP and CKP CtBP2 KO
cell lysates for luciferase using GAPDH as control.

Figure S1 3: Changes in body weight of NSG mice bearing CKP and CKP CtBP2 KO tumors.
Increased body weight of NSG mice orthotopically injected with CKP cells when compared to
that of CKP CtBP2 KO cohort mainly due to increased accumulation of ascitic fluid.
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3
3.1

Chapter 3: Role of p38MAPK-ARF-CtBP2 axis in progression of PDAC
Abstract:

Transcriptional coregulators C-terminal binding proteins 1 and 2 (CtBP 1 and 2) have been
implicated as oncogenes in multiple cancers, and their overexpression was often shown to be
associated with poor prognostic outcomes. In the current study, we attempted to demonstrate the
oncogenic role of CtBP2 in the progression of PDAC using a variation of the KPC pancreatic
conditional mouse model that includes a combination of mutated Kras with one allele of Tp53
deleted, which bears a close resemblance to the genetic events that occur in human PDAC patients.
CKP het mice develop precursor PanIN lesions driven by oncogenic Kras, and with further allelic
loss of p53, PanIN lesions progress to PDAC with a latency period of 7-8 months. Based on
previous reports showing that interaction between CtBP2 and p14ARF (mouse p19ARF) leads to
proteasomal degradation of CtBP2, and preliminary data suggesting direct regulation of ARF by
p38MAPK, we show that inhibition of p38MAPK inhibitor treatment (SB 203580) in three-monthold CKP het mice greatly accelerates the progression of PanINs to PDAC. Moreover, CtBP2 is
upregulated in mice treated with p38MAPK inhibitor, with a concomitant ablation of p19ARF
levels. Our results suggest that CtBP2 protein is intrinsically regulated by p38MAPK via p19ARF.
Our work establishes a putative role of the p38MAPK-p19ARF-CtBP2 axis in the regulation of
PDAC progression. This axis could be further explored to provide potential therapeutic advantage
to PDAC patients. Due to the druggable nature of CtBP2, we propose that a combination of CtBP2
inhibitors with p38 activators could be an effective treatment strategy to inhibit progression of
PanINs to PDAC. We also caution against the use of p38MAPK inhibitors as anti-inflammatory
agents in patients predisposed to develop PDAC, as based on our data, this might trigger PDAC
progression.
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3.2

Introduction

The transcriptional coregulators C-terminal binding proteins 1 and 2 (CtBPs) have been reported
to be overexpressed in multiple cancers and often associated with worst prognostic outcomes
(Barroilhet et al., 2013a; LM Bergman & Blaydes, 2006; Straza et al., 2010). CtBP 1 and 2 play
multiple roles in promoting tumorigenesis including transcriptional repression of pro-apoptotic
genes, activation of Epithelial Mesenchymal Transition (EMT) and promotion of cancer stem cell
formation (M Grooteclaes et al., 2003; Patel et al., 2014b; Stankiewicz et al., 2014). In a recent
report, we documented that deletion of an allele of Ctbp2 in CKP mice with PDAC resulted in
decreased overall tumor burden, along with a significant increase in survival. Interestingly, we also
observed a drastic reduction in oncoprotein c-myc levels with loss of an allele Ctbp2, although the
exact mechanism was not explored (A. T. Chawla et al., 2018). This finding shed new light on the
possible role of CtBP2 in PDAC, which necessitates further investigation.
PDAC is a devastating disease with a five-year survival rate below 10%, and thus, therapeutic
advances in this disease are critical (Güngör et al., 2014). Four major genes- KRAS, CDKN2A,
TP53 and SMAD4- have been reported to be frequently altered in human PDAC patients
(Westphalen & Olive, 2012). The tumor suppressor CDKN2A encodes p16INK4A and p14ARF
(human) /p19ARF (mouse) proteins. Alterations in p14ARF, mainly inactivation, was reported in
human PDAC patients. Studies in transgenic mouse models with homozygous deletion of p19Arf
with mutant Kras background showed that p19ARF plays a vital role in PDAC progression (Aguirre
et al., 2003). Earlier, it was reported that the C-terminus of CtBP2 interacted with p14ARF which
led to the proteasome mediated degradation of CtBP2 (S Paliwal et al., 2006). Furthermore,
preliminary data indicates that degradation of CtBP2 by p14ARF depends on serine 52
phosphorylation of p14ARF by phosho-p38MAPK (an activated form of p38MAPK; Rio
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Boothello et al. unpublished). These findings reveal a dynamic association between p38MAPK,
p14ARF and CtBP2.
Phospho-p38MAPK levels show a strong positive correlation with prolonged survival of resected
PDAC patients (Zhong et al., 2014). Further, in vitro studies have revealed increased proliferation
of human PDAC cells upon inhibition of p38MAPK using chemical inhibitors. This was mainly
due to the compensatory activation of JNK pathway upon p38 inhibition. Moreover it was reported
that inhibition of p38MAPK upregulates MEK/ERK-mediated cell proliferation in PANC-1 cells
(X.-Z. Ding & Adrian, 2001). These findings corroborated our hypothesis that inhibition of
p38MAPK accelerates progression of PanINs to PDAC.
In the present study, we aim to understand the role of the p38MAPK-ARF-CtBP2 axis in
progression of PDAC using a CKP het mouse model. We document that inhibition of p38MAPK
using SB203580 accelerates the conversion of mouse PanINs to invasive carcinoma. We
demonstrate that inhibition of p38MAPK upregulates CtBP2 protein levels with a concomitant
decrease in p19ARF protein levels. Thus, the current study opens up new avenues that could
possibly combine p38 activators and CtBP2 inhibitors as a prevention strategy to delay PDAC
progression.
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3.3

Materials and Methods

3.3.1 Mouse Models and Animal Treatments
(Pdx1-Cre;LSL-KrasG12D,p53+/flox,Ctbp2+/+,

known

as

CKP

het)

and

(Pdx1-Cre;LSL-

KrasG12D,p53+/flox,Ctbp2+/-, known as CKP het 2) with C57BL/6 background were generated by
VCU Transgenic/Knockout Core using standard protocols as described by (Bardeesy et al., 2006).
The animals were maintained in a pathogen free VCU Massey Cancer center animal core. The
pancreas was isolated and analyzed at different time points to understand the PDAC progression.
SB-203580 (p38 inhibitor) was purchased from Selleckchem, Cat. No S1076, and 3-month-old
animals were intraperitoneally injected with 50mg/Kg or 10mg/Kg or Vehicle for three times a
week for six weeks or one week. The study protocol was approved by Institutional Animal Care
and Use Committee at Virginia Commonwealth University.
3.3.2 Histology & Immunohistochemistry
The pancreatic tumor tissues upon isolation were fixed in 10% formalin for 24hrs. Later, paraffin
embedded and serially sectioned. The paraffin embedded sections were Hematoxylin and Eosin
stained using routine procedures. For immunohistochemical staining slides are hydrated with a
series washing steps in graded alcohols and antigen unmasking was performed using Retriver2100
(Retrievagen pH 6.0). Followed by a series of washing steps in PBS, the sections were blocked
using 0.1% Bovine Serum Albumin in (1X) PBST for 1hr at room temperature. After washing in
PBST the slides were incubated with primary antibody in 0.1% BSA in (1X) PBST overnight at
4°C. The primary antibodies used were CtBP2 (Goat polyclonal; 1:200; Santacruz sc-5966),
phospho-ATF2 (Rabbit polyclonal; 1:50; Cell Signaling Car. No 9221), p19ARF (Rabbit
polyclonal; 1:200; Abcam ab80). Following overnight incubation with primary antibody, sections
are washed in 1X PBST for three times before incubation with secondary antibody for 1hr at room
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temperature. Following DAB staining and hematoxylin counter staining the slides are cover
slipped. The IHC images were quantified by scoring the staining intensity (0-3 scale with 0:no
staining, 1: Weak staining, 2: Moderate staining, 3: Intense staining).

3.3.3 Statistics
All the data shown was analyzed using GraphPad prism 8.4.1 and is represented as mean ±SEM.
Paired t-test was performed to find the significant difference between the two groups and p-value
was reported. p <0.05 was reported to be significant difference between the groups.
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3.4

Results

3.4.1 Combined loss of an allele of p53 and oncogenic K-Ras activation contributes to
formation of mouse PanINs which slowly progress to PDAC
Mutation of the K-RAS oncogene with inactivation of tumor suppressors, such as CDNK2A, p53
and SMAD4 was reported in the majority of human PDAC patients (Westphalen & Olive, 2012).
In an effort to recapitulate human PDAC, and understand the role of tumor suppressors, several
transgenic mouse models were generated by homozygous or heterozygous deletion of tumor
suppressors, mainly p16/p19Arf/p53, with a background Kras mutation (Aguirre et al., 2003;
Hingorani et al., 2003). In the majority of models, mice develop precursor lesions which progress
to invasive carcinoma with a very short (<12 weeks) latency. In the current study, the pancreata of
CKP het mice were microscopically examined for morphological changes at various time points,
and we observed that CKP het mice start to develop low grade PanINs at an age of 2-3 months,
which transformed to high grade PanINs 2/3 in 4-5 months, and finally to invasive PDAC after 78 months (Figure 3-1A-B). The median survival of CKP het mice was 20.5 weeks and of note,
they rarely developed metastatic tumors in distant organs.
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Figure 3-1: Loss of an allele of p53 with activated oncogenic KrasG12D leads to the development
of PanINs that progress to PDAC. A. The time line for the progression of PanINs to PDAC in a
CKP het mouse model. B. Representative H and E sections of pancreas obtained from (a) 2 (b) 3
months old mice with low grade PanINs and (c) 5-month-old with high grade PanINs (d)PDAC
formed in 8 months old mice.

3.4.2

Inhibition of phospho-p38MAPK accelerates the conversion of precursor PanIN
lesions to Invasive Ductal Adenocarcinoma

Earlier studies have shown that inhibition of p38MAPK increased the proliferation of pancreatic
cancer cells (X.-Z. Ding & Adrian, 2001; Zhong et al., 2014). Intraperitoneal injection of
p38MAPK inhibitor SB203580 (50mg/Kg or 10mg/Kg) into three-month-old CKP het mice with
minimal grade PanINs (Figure 3-2A) resulted in accelerated progression to PDAC. For the initial
studies we injected the animals with vehicle vs. SB203580 (50mg/kg) for six weeks and found that
the animals which received SB203580 showed significantly larger pancreas weights when
compared to vehicle treatment (Figure 3-2B, 3-2C). When pancreatic sections were H&E stained,
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we observed that p38 inhibitor treated mice developed invasive PDAC, whereas vehicle treated
mice showed only minimal to high grade PanIN lesions (Figure 3-2B). Also, there was a
significant decrease in survival of mice treated with SB 203580 when compared to the vehicle
(Figure 3-2D).
We next sought to decrease the dose of SB203580 to 10mg/Kg, in order to minimize the
off-target effects if any of p38MAPK inhibition and repeated the study, and interestingly we found
a similar effect of p38 inhibitor treatment upon microscopic examination of H&E stained
pancreatic sections (Figure 3-3A, 3-3B). Quantification of the percentage of area covered by
PanIN lesions vs. PDAC on the pancreatic sections from each mouse revealed significant
progression of pancreatic lesions to PDAC upon SB203580 treatment for six weeks vs. vehicle
(Figure 3-3C, 3-3D). In the vehicle treated group, approximately, 60% of the area of the pancreatic
sections showed PanIN lesions. On the other hand, ~70% of pancreatic sections contained PDAC
with no PanIN lesions in SB203580 treated group. However, when the same p38 inhibitor study
was performed utilizing CKP het mice which had also been bred to heterozygous deficiency of
Ctbp2 (“CKP2 het” strain), no significant difference was observed in the pancreas weight and
morphology between vehicle and SB203580 treatment (Figure S1) , suggesting the necessity of
complete expression of CtBP2 to observe the effect of p38MAPK inhibition on progression of
PanIN’s to PDAC.
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Figure 3-2: Inhibition of p38 accelerates the conversion of PanINs to PDAC. A. Time line showing
treatment of CKP het mice with either SB203580 or vehicle. B. Representative images of pancreas
from the CKP het mice treated with SB or vehicle and H and E sections showing minimal grade
PanINs with pancreatitis in vehicle treatment and PDAC in the SB 203580 treated animals. Scale
200µm. C. Weight of CKP het mice pancreas post three-weeks injection of SB-203580 or vehicle.
D. Overall survival of CKP het vehicle (n=4) vs CKP het p38i (n=5) treated mice. Median survival
for vehicle treated mice was 20 weeks while median survival for p38i treated mice was 17 weeks
(log-rank test, p=0.0065).
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Figure 3-3: Dose dependent effect of p38 inhibition on acceleration of PanINs to PDAC. A.
Increased weight of pancreas upon treatment of CKP het mice with SB 203580 (10mg/Kg) or
vehicle. B. Representative H and E stained sections of pancreas showing low grade PanINs
(arrows pointed) in vehicle treatment compared to PDAC with desmoplastic reaction and
enlarged nuclei in SB 203580 (10mg/Kg) treated mice. C. Quantification of % of Total PanINs
and D.% of invasive cancer/PDAC post vehicle or SB treatment. Paired t-test was used to test
the difference between the groups. Data shown as mean± S. E. M (n=3/group).
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p38MAPK inhibitor upregulates CtBP2 via degradation of p19ARF
Based on the known regulation of ARF and CtBP by p38MAPK (R. Boothello et al unpublished),
along with the striking changes in histology observed after p38 inhibition in CKP het mouse
pancreata, we performed immunohistochemical staining for Ctbp2 and p19Arf proteins in pancreas
sections from CKP het mice treated with vehicle vs. SB203580. We found intense accumulation
of p19ARF protein in the PanINs of vehicle treated mice, while the mainly PDAC regions of
pancreata from p38 inhibitor treated mice showed negligible levels of p19Arf, while exhibiting
intense accumulation of nuclear CtBbp2 (Figure 3-4A). The accumulation of p19ARF in PanINs
after vehicle treatment could be due to stress activated p38MAPK, restraining PDAC conversion.
However, upon inhibition of p38MAPK, p19ARF levels were reduced, possibly facilitating the
conversion to PDAC. When the IHC staining was scored based on a staining intensity scale (0-3),
there was a significant increase in CtBP2 protein levels, along with decrease in p19ARF levels,
after p38 inhibitor treatment (Figure 3-4B, 3-4C).
We further refined our investigation of the timing by which PanINs converted to PDAC
after p38 inhibitor treatment by limiting SB 203580 or vehicle treatment to one week instead of
six weeks. After one week of treatment, we observed an increase in the total area of PanIN lesions
in tissue sections from mice treated with SB203580, when compared to vehicle. Upon
immunohistochemical staining of pancreatic tumor sections for CtBP2, we also found a significant
increase in CtBP2 protein levels (Figure 3-5). We confirmed p38MAPK inhibition by staining the
tumor sections with a surrogate marker for p38 kinase inhibition, phospho-ATF2, a downstream
effector of the p38 pathway, and found that phospho-ATF2 levels decrease upon treatment with
SB203580 (Figure 3-5) (X.-Z. Ding & Adrian, 2001). The results confirmed that the effect of
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p38MAPK inhibition on PanIN-PDAC progression and on levels of CtBP2 via p19ARF, correlate
with a true decrease in the kinase activity of p38MAPK toward a validated target.

Figure 3-4: Inhibition of p38 upregulates CtBP2 via degradation of p19ARF.A. Representative
H and E pancreatic tumor sections (top panel) from both vehicle (left) with low grade PanINs
and SB203580 treated (right) with PDAC. CtBP2 and p19ARF immunostaining of tumor
sections from vehicle and SB 203580 treated mice. Quantification of IHC scoring based on
staining intensity (Scale 0-3) of (B)p19ARF and (C) CtBP2. Paired t-test was used and the data
presented as mean with S. E. M (n=3/group). Scale bar 50µm.
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Figure 3-5: Effect of CtBP2 and p19ARF upon inhibition of p38MAPK. Pancreatic sections of
mice treated with either vehicle or SB 203580 for a week. H&E (top panel) sections showing
minimal grade PanINs and (Lower panels) immunohistochemically stained for CtBP2, p19ARF
and phospho-ATF2 proteins. Scale bar 50µm.
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3.5

Discussion

In the current manuscript we attempt to demonstrate the putative role of the p38MAPK-CtBP2p19ARF axis in the progression of PanINs to PDAC, using a CKP het mouse model. Our results
show that inhibition of p38MAPK kinase activity using the chemical inhibitor SB203580
accelerates the conversion of PanINs to PDAC. Immunohistochemical analysis revealed an
upregulation of CtBP2 protein levels with concomitant downregulation of tumor suppressor
p19ARF in pancreata of p38 inhibitor-treated mice. In a recent study, we showed that deficiency
of CtBP2 in a PDAC mouse model resulted in decreased metastasis, although the exact mechanism
was not clear (A. T. Chawla et al., 2019). In addition, human PDAC patients at various stages
heavily expressed CtBP2 protein which hints at a possible role for CtBP in PDAC.
Of the several tumor suppressors that were inactivated/lost in PDAC development,
CDKN2A, which codes for p16IN4A and p14ARF (p19ARF in mouse), is often deleted in a subset
of human PDAC specimens (Bardeesy et al., 2006). Transgenic mouse models in which Kras
mutation is coupled with deletion of p16/p19Arf led to the development of metastatic pancreatic
invasive carcinoma (Aguirre et al., 2003). These models were valuable tools to identify role of
tumor suppressors p14/p19Arf in PDAC. Previously, CtBP2 was shown to interact with p14ARF
in colon carcinoma cells, which led to its proteasome mediated degradation (S Paliwal et al., 2006).
In addition, the interaction of ARF with CtBP2 also led to the upregulation of BH3 pro-apoptotic
proteins that induced apoptosis in cancer cells in a p53 independent manner (Kovi et al., 2010).
Based on these reports we speculated that PDAC progression might depend on CtBP2.
Tumor suppressor p38MAPK has been previously implicated in the progression of pancreatic
ductal adenocarcinoma. Human PDAC patients were reported to express high levels of phosphop38 (activated form) when compared to normal pancreas (Yang et al., 2019). Furthermore, a study
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showed PDAC patients who expressed high levels of pp38 survived longer when compared to
those expressing lower levels, and also inhibition of p38 resulted in increased tumor cell
proliferation of pancreatic cancer cells (Zhong et al., 2014). On the contrary, another study
concluded that inhibition of p38α decreased the cell viability of human PDAC cell lines (Yang et
al., 2019). The above reported studies suggest the dual role of p38MAPK inhibition in PDAC,
which still remains controversial. In an unpublished study we discovered that the phospho-p38p14ARF-CtBP2 axis regulates the cancer stem cell phenotype and tumor dormancy (Boothello et
al., 2018).
To understand putative role of the putative p38-p14ARF-CtBP2 axis in PDAC progression, threemonth-old CKP het mice with low grade PanINs were treated with SB20350 (50mg/Kg) for six
weeks, resulting in rapid progression of PanINs to PDAC. In contrast, the vehicle treated pancreata
showed only minimal to high grade PanINs. However, CKP het 2 mice with allele of Ctbp2 deleted
showed no effect upon inhibition of p38MAPK, this suggested the requirement of complete CtBP2
protein to induce the effects of p38MAPK inhibition. As expected, in CKP het mice we observed
a sharp increase in Ctbp2 protein levels in mouse pancreatic tumors treated with SB203580 when
compared to vehicle treatment. In addition, we also found a decrease in p19Arf levels which
inversely correlated with Ctbp2 protein levels, recalled our previous findings (Straza et al., 2010).
For the first time, we also showed the possible regulation of CtBP2 by p38MAPK in PDAC
progression via p19ARF (Figure 3-6).
Our work has established a putative role for CtBP2 in PDAC progression, and CtBP can be
pharmacologically inhibited (Dcona et al., 2017) , as a means to possibly prevent the progression
of precursor lesions to PDAC. This study presents a fruitful avenue for combining p38 activators
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with CtBP2 inhibitors in the future that could be a potential prevention strategy to arrest PDAC
progression from precursor lesions.

Figure 3-6: Proposed model for regulation of PDAC progression. p38-ARF-CtBP2 axis a novel
regulator of progression of precursor lesion to invasive ductal adenocarcinoma. Cellular and
oncogenic factors lead to activation of p38MAPK which was shown to phosphorylate p19ARF
that interacts with CtBP2 leading to proteasomal degradation of CtBP2. Inhibition of p38MAPK
leads to interferes with CtBP2 degradation accelerating progression of PanINs to PDAC.
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Supplemental Figure

Figure S 1: Effect of p38MAPK inhibition on PDAC progression in CKP het 2 mice. Inhibition of
p38MAPK had no impact on PDAC progression in CKP het 2 mice with precursor PanIN lesions.
No significant difference in weight of pancreas was observed between the vehicle and SB203580
treated groups. Paired test was performed and data represent mean ± S.E.M.
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4

4.1

Chapter 4: Conclusions and Future Perspectives

Role of CtBP2 in PDAC growth and metastasis

Loss of CtBP2 decreases PDAC tumor growth, proliferation, EMT, metastasis and tumor cell
migration, using cell lines and an orthotopic pancreatic tumor mouse model. Our results recall
previous findings, which revealed the oncogenic nature of CtBP2 in PDAC (A. T. Chawla et al.,
2019). Upon mechanistic exploration, multiple oncogenic activities of CtBP2 in PDAC could be
attributed to decreased ErbB3/PI3K signaling upon deletion of CtBP2. Downregulation of
transcriptional factor Znp217(ZNF 217 in humans) concomitantly with Erbb3 upon deletion of
CtBP2 in PDAC tumors, suggests a dependency of possible CtBP2 and ZNP217 interaction for
promotion of ErbB3 gene expression. As a future study, co-immunoprecipitation experiments
could validate such a potential CtBP2-ZNF217 interaction in PDAC cells. Previously, CtBP2 was
shown to regulate ErBB3 gene expression by interacting with ZNF217 in breast cancer cells (Krig
et al., 2010). However, in the current study it is unclear whether the regulation of Erbb3 gene
expression by CtBP2 is by direct physical interaction or indirect. A ChIP assay could reveal if a
ZNP217/CtBP2 complex binds to the promoter region causing transcriptional activation of Erbb3.
These future studies could explain the mechanistic role of CtBP2 in regulating PDAC growth.
Another question that needs further investigation is, why do Ki67 levels decrease with loss of
CtBP2? Does CtBP2 impact the cell cycle regulation in PDAC? It would be interesting to conduct
experiments, which identify the status of cell cycle regulators, such as cyclins, cdk’s and cdk
inhibitors, between the two cohorts (CKP and CKP CtBP2 KO).
Next, we sought an explanation for decreased metastasis and EMT upon deletion of CtBP2.
Trans-well migration studies performed in CKP cell lines validated the in vivo findings. However,
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future migration studies using different PDAC cell lines will further strengthen our understanding
of regulation of tumor cell migration by CtBP2. The protein levels of EMT markers E-cadherin
and vimentin varied upon deletion of CtBP2 in a manner which supports a role for CtBP2 in EMT
in PDAC. However, further experiments are needed to conclude if CtBP2 transcriptionally
represses E-cadherin to promote EMT, as in previous studies (Yu Deng et al., 2012). Nonetheless,
the study results gained new insights into possible roles of CtBP2 in PDAC.
In addition, our studies revealed the possibility of using CtBP2 inhibitors for the treatment
of PDAC, based on the in vitro cytotoxicity assays performed. The IC50 value for 4-Cl HIPP was
in millimolar range, however, upon combining the CtBP2 inhibitor with a PI3K inhibitor, 0.75fold greater cytotoxicity was observed in CKP cell line when compared to 4-Cl HIPP alone
treatment. In addition, combining CtBP2 inhibitor with an ERBB3 inhibitor, also brought down
the 4-Cl HIPP IC50 into the micromolar range in CKP CtBP2 KO cells. However, testing with
more potent EGFR inhibitors like Osimertinib, AZD 8931, or Gefitinib could improve study
outcomes.
Finally, our studies suggest testing the combination of CtBP2 inhibitors and ERBB3/PI3K
inhibitors in vivo could be a promising treatment paradigm for PDAC.
4.2

Role of p38MAPK-p19ARF-CtBP2 axis in progression of PDAC

From the study results, we conclude that inhibition of p38MAPK accelerates the progression of
PanINs to PDAC. Our findings drive our hypothesis that inhibition of p38MAPK upregulates
CtBP2 via down regulation of p19ARF. We have established the p38MAPK-ARF-CtBP2 axis as
a novel regulator of PDAC progression. This finding could be used in the future to develop novel
therapies combining CtBP2 inhibitors with p38 activators, to prevent the progression of PanINs to
PDAC. One of the major caveats of the current study is lack of proof of concept. However, future
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in vitro cell proliferation assays in pre-malignant ductal cells treated with p38MAPK inhibitor will
provide sufficient evidence to validate the study findings. In addition, the current study does not
interrogate the role of the tumor micro-environment. It is unclear if the p38MAPK signaling of
tumor cells, stromal cells, or immune cells is altered. Further, delineating which of these cells
contribute to tumor progression would be interesting, as the tumor microenvironment of PDAC is
extremely heterogenous and strongly contributes to the tumor phenotype.
Lastly, the status of phospho-p19ARF in PanINs is still undetermined as we probed for
p19ARF but not phospho-p19ARF. Currently, no antibody exists to probe for phospho-p19ARF
protein, therefore performing in vitro immunoprecipitation assays would reveal changes in
phosphorylated p19ARF upon p38MAPK inhibition.
Testing the applicability of the concept of the phospho-p38MAPK-p19ARF-CtBP2 axis in other
PDAC mouse models will be important for validating our findings as broadly applicable to PDAC
tumor progression.
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I.

Appendix I: Extraction of high-quality RNA from pancreatic tumors

A.1-1 Abstract
Extraction of high-quality RNA from pancreatic tumors for sequencing purposes is technically
challenging, as the pancreas is an organ rich in ribonucleases. The majority of the established RNA
isolation protocols for use with primary pancreatic tissue involve perfusion of RNAlater into the
pancreatic tissue to protect the RNA integrity before extraction. However, the additional time
needed for this procedure can actually lead to further RNA. We optimized a protocol suitable for
RNA isolation from mouse pancreatic tumors that is a simple, fast and inexpensive modification
of existing methods, combining the use of liquid nitrogen and Trizole-chloroform. Through this
procedure the RIN values obtained were up to 10, and the high-quality RNA isolated from mouse
pancreatic tissue was reproducibly suitable RNAseq and QPCR.

A.1-2 Introduction
Pancreatic cancer remains among the most lethal cancers (Rawla et al., 2019). with a case fatality
rate of over 90% (Keleg et al., 2003). Transgenic mouse models of pancreatic cancer have
contributed critical understanding to mechanisms of disease progression and therapeutic resistance
characteristic of this aggressive and refractory cancer (Melstrom & Grippo, 2008; Westphalen &
Olive, 2012). Next generation sequencing (NGS) technologies developed are powerful tools to
identify dysregulated signaling pathways in cancer, that often lead to identification of novel targets
and development new therapeutic interventions (Cullum et al., 2011). High quality RNA from
mouse pancreatic tumors could be an excellent source to identify altered gene expression using
RNA sequencing technology (Augereau et al., 2016). Extracting high quality intact RNA is
extremely important to be able to perform sequencing studies and analyze differential gene
expression. Degraded RNA or poor-quality RNA can often bias results and is not suitable for
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sequencing purposes (Gallego Romero et al., 2014). In addition to biasing the results the exorbitant
sequencing costs that incur with sequencing highlight the importance extracting pure quality RNA.
RNA extraction is one of the simple and common techniques
performed in many labs on a daily basis to quantify mRNA levels by using quantitative Polymerase
Chain Reaction (qPCR). For qPCR procedures the RNA quality is usually estimated by measuring
the absorbance at 260nm and 280nm using a spectrophotometer. The absorbance ratio of A260/A280
is calculated, a ratio of ~2.0 is considered as pure RNA quality. However, this ratio does not
represent the quality of intact RNA and it is not reliable for sequencing purposes. For example, the
RNA samples with A260/A280 ratio 2.1 have poor RIN values. Hence, for the sequencing purposes
the RNA quality is measured is using Bioanalyzer 2100. Bioanalyzer2100 is a chip-based machine
that works on the principle of capillary electrophoresis and is used in analyzing the quality of
DNA, RNA and protein. The quality of RNA for Next Generation Sequencing (NGS) platforms is
assessed by Bioanalyzer using a RIN (RNA Integrity Number) value which ranges from 1-10, with
10 representing the highest quality RNA. The major factors that affect the quality of isolated RNA
include extraction method, DNA contamination, temperature of the extraction, processing time
and storage. In the current study we report optimal conditions for extraction of high-quality RNA
from mouse pancreatic tumors.
The established triazole method is most commonly used method for
the extraction of RNA from cells and tissues (Rio, Ares, Hannon, & Nilsen, 2010). Although, this
method is suitable for extracting high quality RNA from most organs, this method is not ideal for
pancreatic RNA extraction, as the pancreas is enriched with ribonucleases (Lenstra & Beintema,
1979) which degrade RNA. Previously reported studies for extraction of high quality RNA from
murine (Azevedo-Pouly et al., 2014; Griffin et al., 2012; Lisle, 2014), rat (Dastgheib et al., 2014),
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and human pancreatic tissue (Jun et al., 2018). However, these methods are complex, expensive,
and requiring substantial time and special skills. Most of these reported methods employ the use
of triazole, and in the majority of these studies, the RNA quality is assessed using the A 260/A280
ratio (Desjardins & Conklin, 2010). In the other studies which used Bioanalyzer2100 to estimate
the quality of RNA the average RIN value was around 9. As such, no studies demonstrating the
extraction of high-quality RNA from mouse pancreatic tumor tissue have been reported in
literature. Here, we have optimized a previously reported simple RNA isolation method that
reproducibly results in extraction of high-quality RNA (RIN ~10) from mouse pancreatic tissue
and tumors. We also review the pros and cons of different extraction procedures including tips for
obtaining optimal RNA quality that is suitable for sequencing purposes.
The procedure to extract high quality RNA from pancreatic tumors is outlined
in Figure A1 1. The first step is to isolate the pancreatic tumors from mice under ice cold
conditions and as quickly as possible to avoid the possible degradation of RNA by RNases released
from pancreas. The next step is storage of the isolated tumors which could be performed either by
flash freezing the tumors in liquid nitrogen and storing at -80C till the extraction or by storing in
RNAlater at room temperature/-20C based on estimated time before extraction. The most
important step is the extraction of RNA from tumors frozen tumors using phenol-chloroform
method after powdering the tumor tissue using adequate liquid nitrogen. Finally, isolating the pure
RNA using QIAGEN RNaeasy extraction kit treated with DNase to get rid of DNA contamination.
The quality of RNA is checked by bleach gel electrophoresis as described by (Aranda et al., 2012)
before sending to bioanalyzer.
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Figure A1 1: Workflow for the extraction of high-quality RNA from mouse pancreatic tumors.
A) Isolating pancreatic tumors from mice after dissection. B) Isolated tumor tissues are
triturated using liquid nitrogen and extracted using Triazole C) addition of chloroform to the
triazole triturate followed by vigorous shaking D) Isolation of pure RNA using QIAGEN
RNeasy mini-plus extraction kit as per the manufacturer specifications E) Quality checking of
the isolated RNA using Bioanalyzer 2100.

A.1-3 Materials

NSG Mice four-month-old (IACUC approved)
Liquid Nitrogen
Triazole (Ambion, CA)
Chloroform (Pharmaco, USA)
100% Ethanol
RNaseZap Wipes (Ambion, USA)
DNase/RNase free pipette tips (VWR, PA)
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Nuclease-Free Water (Ambion, Austin, TX)
RNeasy mini-plus kit (QIAGEN, Germany)
RNase-Free DNase set (QIAGEN, Germany)
RNAlater (SIGMA Life Science, USA)
A.1-4 Equipment

Chemical hood
Mortar and pestle
Surgical equipment
Agilent Bioanalyzer 2100 (USA)
Nanodrop 1000 Spectrophotometer (Thermo Scientific, USA)
Synergy H1 Hybrid Plate reader (BioTek, Vermont, USA)
Homogenizer (Bio-Gen PRO200, USA)
A.1-5 Protocol
Step 1: Isolation and freezing of Pancreatic tumors
1.1. The use of animals for the study was approved Institutional Animal Care and Use
Committee of Virginia Commonwealth University.
1.2. For the study we injected four-month-old NSG mice with 8x105 cells of a mouse PDAC
cell line orthotopically into pancreatic tail vein and allowed the tumor cells to grow for
three weeks before euthanizing the mice.
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1.3. Prior to the extraction, decontaminate the entire workspace and surgical equipment used
in isolation pancreatic tumors with 70% ethanol and RNase Zap Wipes.
1.4. NSG mice bearing pancreatic tumors were anesthetized using isoflurane and euthanized
by cervical dislocation. After euthanizing, the mice were fixed on to the dissecting table
with ventral side facing upwards. Sterilize the abdominal area using 70% ethanol and
make an incision in the genital area, now cut open longitudinally to expose the abdomen.
Now move bowels towards the left side to get a clear picture. As pancreatic tumors are
evident unlike the normal pancreas make an incision at the common bile duct and isolate
pancreas quickly using scissors and forceps. The whole process need not be carried out
under sterile conditions if it’s for RNA extraction. Follow this reference on how to isolate
the mouse pancreas.
1.5. If only a part of the whole pancreatic tumor is needed, cut the tumor while soaked in
RNAlater quickly in a petri-dish on ice, then transfer it to a vial/Eppendorf tube and drop
in liquid nitrogen to flash freeze the tumor tissue. Transfer the flash frozen tumor vials to
-80C until extraction.
1.6. Tip: Be as quick as possible and try to maintain cold conditions as much as possible.
1.7. Tip: Mince the tumor or pancreas into small pieces while soaked in RNAlater, as this
facilitates later steps. Mincing the tumors could possibly improve penetrability of
RNAlater and retains integrity of RNA in the tissues.
1.8. Tip on use of RNAlater for storage: Soak the tissue in RNAlater before extraction and
store as recommended by the manufacture specifications. We recommend it only for the
longer-term storage of pancreatic tumors, usually for a next day extraction, snap freezing
in liquid nitrogen works effectively and gives the best results.
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Step 2: Extraction of RNA
2.1. Manual Extraction: Before performing manual extraction, clean the mortar and pestle
using RNaseZap Wipes.
2.2. Weigh and transfer the tumor tissue from the flash frozen vial into the mortar, and powder
the tissue while adding liquid nitrogen to the mortar that makes the tissue easier to powder,
make sure everything is cold. Do not allow the tissue to thaw for optimal results.
2.3. To the powdered tissue add Triazole (Ambion) 500l each time, two times for the tumor
tissue weighing up to 100mg and continue trituration (Figure A1 2). We recommend up
to 1ml of triazole per 100mg of tumor tissue for a good yield. It is ideal to carry out
trituration in a chemical hood to avoid hazardous health effects of the Triazole. The
mechanism by which Triazole works is it retains the RNA integrity by disrupting the cell
wall and cellular contents.
2.4. Transfer the triazole triturate, after it is liquefied, to the DNase/RNase free Eppendorf
tube, and incubate for 5 mins at room temperature. It is common to observe solidification
of the triturate which liquifies upon on continuing further trituration for longer time.
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Figure A1 2: Manual extraction procedure of RNA from mouse pancreatic tumors using liquid
nitrogen and triazole. (A) add the pancreatic tumor tissue to the mortar and (B) powder the tissue
by adding liquid nitrogen (C) triturate further by adding triazole to the powdered tissue.
2.5. Electrical Homogenization: Transfer the frozen tumor tissue to a beaker on ice and add
up to 1ml triazole for up to 100mg tissue and homogenize for 15 sec using electrical
homogenizer (Bio-GEN Pro 200) at medium speed. The ratio of tissue/triazole needs to
be optimized for better results by performing the homogenization for different times
periods.
2.6. After homogenization transfer the triazole homogenate to a new DNA/RNase free
Eppendorf tube at room temperature and incubate for 5 minutes.
2.7. Later, add 200l chloroform per ml of Triazole lysate and shake vigorously for 15 sec and
incubate the tube for 2-3mins at room temperature before placing in the pre-cooled
centrifuge at 4°C for 11600 rcf for 15mins.
2.8. Centrifugation results in separation of the two phases (chloroform aids in separation
aqueous phase and lower organic phase) in the Eppendorf tube. Now, carefully transfer
the upper clear supernatant layer without agitation to a fresh Eppendorf tube and mix with
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0.5x volume of 100% ethanol. Ethanol mainly helps in precipitating out nucleic acids
(DNA, RNA) from aqueous solutions.
2.9. Tip: Try not to disrupt the bottom tissue layer, this will result in blocking the RNA spin
column and decreases the efficiency of the method.
2.10. Tip: With electrical homogenization there is chance of observing ribosomal peaks as
shown in Figure 2A (could be due to over homogenization if not done carefully) and the
possible degradation of RNA by could be by the heat generated. This step needs to be
optimized as per the requirement.

Step 3: Purification and Isolation of RNA
3.1. After mixing with ethanol, transfer the mixture to the QIAGEN RNeasy mini kit spin
column centrifuge and centrifuge at 9600rcf for 30sec.
3.2. Wash the column using 350 ul RW1 wash buffer from the RNeasy mini extraction kit.
3.3. Add 40μl of freshly prepared DNase I solution (Thermo Fisher) and incubate the column
for 15 min at RT, after which, wash the column with RW1 wash buffer for the second time
and centrifuge at 9600rcf for 30sec.This makes the extract free from DNA contamination.
3.4. Discard the flow through, and wash the column with 500µl RPE buffer supplied in the kit
two times at 9600rcf for 30sec.
3.5. Finally spin the column at 16000rcf for 2min to remove any remaining RPE buffer from
column. Make sure you remove the RPE buffer completely for better results.
3.6. Add 30-40µl of RNase free water to the column and incubate the column for 1 min at
room temperature.
3.7. Centrifuge at 9600rcf for 30sec to collect the pure RNA.
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3.8. Tip: Avoid including tissues pieces in the solution, that might result in blocking of the
column and reduce column efficiency.
3.9. Tip: As the binding affinity of the RNase easy spin columns is limited, we recommend
dividing the extract and run using multiple columns and combine the eluates.
3.10. Tip: Avoid repeated elution as most of the RNA obtained by repeated elution is not high
enough quality for sequencing purposes.

Step 4: Quantification of RNA
4.1. The concentration of RNA is measured using Nanodrop by loading 2µl of the sample.
4.2. The concentration and the absorbance ratio A260/A280 value obtained in nanodrop gives an
estimate of concentration and quality.
4.3. However, 260/280 value is not a determinant of intact RNA, so make sure you have
sufficient RNA for the quality check and sequencing steps.

Step 5: Quality Check
5.1. The integrity of the RNA was checked using Bioanalyzer 2100 (Agilent technology) by
following the standard protocol for running total eukaryotic RNA on a pico chip.
5.2. Analyze the quality of the RNA as shown in Figure A1 3 using RIN values, RNA Integrity
Number.
5.3. The extracted RNA is stored at -80C till used for sequencing.
5.4. Tip: Run the RNA samples on an agarose gel as described by (Aranda et al., 2012) and
look for 18s and 28s band before sending the samples as shown in Figure A1 4 for
Bioanalyzer quality check which is economical.
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5.5. Tip: Avoid multiple freeze thaws, divide the RNA isolate into multiple aliquots and
storage at -80C. Use each aliquot for definitive purposes.
5.6. Tip: Use dry ice to transfer the samples for quality check or sequencing to protect the
integrity.

Figure A1 3: Extraction after flash freezing maintains RNA integrity. The integrity of RNA
(RIN values) isolated from pancreatic tumors A) soaked in RNAlater extracted with Triazole
on ice and B) flash frozen tumors powdered using liquid nitrogen and extracted with Triazole.
C) Mean+/- SEM, (n=6). *p< 0.005.
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Figure A1 4: Determining the quality of RNA by bleach gel electrophoresis. Representative
sample RNAs extracted using the technique of flash freezing of tumors followed by triazolechloroform extraction. Quality assessed by ratio of 28S/18S band intensities on the gel which is
~2.0.

Step 6: Storage
6.1. The extracted RNA is stored at -80C till use.
6.2. Tip: It is advisable to use the RNA as early as possible to avoid the possible degradation
issues.
A.1-6 Concluding remarks
Although numerous methods have been published which describe the extraction of highquality RNA from pancreas, our method is simple, reliable and reproducible, resulting in
extraction of high-quality RNA especially for sequencing purposes. Incorporation of these
simple tips will help greatly in improving the quality of RNA and make it usable for the
sequencing purposes, saving a lot of money and avoiding the bias in the sequencing results.
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II.

Appendix II: Mechanism of apoptosis induced by 4-Cl HIPP

One of the hallmarks of cancer is to evade apoptosis, and CtBP1/2 were reported to repress
proapoptotic gene expression programs and confer apoptotic resistance to tumor cells (LM
Bergman & Blaydes, 2006; B. Ding et al., 2020; M Grooteclaes et al., 2003; Kovi et al., 2010;
Xuan et al., 2017). Previously, transient depletion of CtBP2 in Human Colorectal Tumor (HCT
116) cells resulted in upregulation of pro-apoptotic gene BIK expression (Kovi et al., 2010). Taken
together, these findings implied an inverse relationship between CtBP2 activity and apoptosis.
The transcriptional activity of CtBP2 was attributed to its dehydrogenase domain, targeted by
using small molecule inhibitors like MTOB (methylthio-2-oxobutyric acid), HIPP (2hydroxyimino-3-phenyl propionic acid), 3-chloro HIPP and 4-Cl HIPP (A. T. Chawla et al., 2018;
Chinnadurai, 2002; Korwar et al., 2016; Straza et al., 2010; Evan T. Sumner, 2016). Of the several
CtBP2 inhibitors tested, 4-Cl HIPP is the most potent (Korwar et al., 2016). Surprisingly, 4-Cl
HIPP’s CtBP2 inhibitory activity was experimentally documented, but the underlying mechanistic
details of induced cytotoxicity are still unknown.
Despite CtBP2 being considered as an attractive therapeutic target to treat cancer, the major
impediment for the clinical development of inhibitors like 4-Cl HIPP is the lack of understanding
of their mechanism of action. We aimed at investigating the mechanism of action of 4-Cl HIPP to
provide valuable insights for developing effective combination therapies for treatment of various
cancers.
When HCT116 cells were treated with 4-Cl HIPP, we observed cytotoxicity in the millimolar
concentration range (Figure A2 1). Based on this finding, we sought to understand the mechanism
of cell death, and indeed, 4-Cl HIPP induced apoptosis as confirmed by Annexin V and PI staining
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(Figure A2 2A). There was a dose dependent increase in % of apoptotic cells upon treatment with
4-Cl HIPP (Figure A2 2B). This was further confirmed by increased cleaved caspase-3 levels
upon treatment with 4-Cl HIPP (Figure A2 3A). We also identified that apoptosis induced by 4Cl HIPP was caspase dependent (Figure A2 3B). Pre-treatment of HCT116 cells with ZVAD, a
pan-caspase inhibitor led to inhibition of PARP cleavage induced by 4-Cl HIPP (Figure A2 3C).
We further explored changes in pro-apoptotic gene expression programs upon treatment with 4-Cl
HIPP. We found an increase in mRNA levels of pro-apoptotic genes BIK, NOXA and BMF upon
treatment with 4-Cl HIPP, which recalled previous observations (Figure A2 4) (Kovi et al., 2010;
Straza et al., 2010).
Through these studies we were able to identify activation of the intrinsic caspase-3 dependent
apoptotic pathway in tumor cells upon treatment with 4-Cl HIPP. These results present a
mechanistic insight into the mode of cytotoxic action of 4-Cl HIPP. However, further studies are
needed to delineate the exact mechanism of cytotoxic action of 4-Cl HIPP.
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Results

Figure A2 1: 4-Cl HIPP is cytotoxic to colon cancer cells. HCT116 cells were treated with 4-Cl
HIPP (0,0.25 ,0.5, 0.75, 1, 1.25,1.5,1.75 and 2mM) for 48 hrs. Cell viability was determined by
crystal violet staining. Data presented is mean of four experiments ± SEM. p value was determined
by performing Paired t test (Two-tailed). ***P<0.05, ****P<0.0001.
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Figure A2 2: 4-Cl HIPP induces apoptosis in HCT116 cells. A. Apoptosis induced was detected
by flow cytometry using Annexin V-allophycocyanin conjugate and Propidium Iodide dual
staining upon treatment with 4-Cl HIPP at various doses for 48 h. B. Graph showing % of apoptotic
cells (sum of cells in right hand quadrants) following the treatment. Data presented is mean ± SEM
of three independent experiments. p value is obtained by performing paired t test. p value < 0.05
was considered to be significant difference between two groups.

104

Chougoni 2020

Figure A2 3: 4-Cl HIPP induces caspase 3 mediated apoptosis. A. Representative flow cytometric
analysis of HCT116 cells after treatment with 4-Cl HIPP at 0, 0.3, 0.6, 0.9 and 1.2mM for 48hrs
using cleaved caspase 3 antibody. B. Graph showing percentage of cells positive for cleaved
caspase 3. Data represented is mean ± SEM of three independent experiments. C. Immunoblotting
of lysates from HCT116 cells treated with 4-Cl HIPP for 48 hrs for PARP, cleaved PARP, caspase
3, and corresponding GAPDH protein levels; detection of full length PARP (116 kDa),
corresponding PARP cleavage band (89 kDa), cleaved caspase 3 and GAPDH is shown. D.
HCT116 cells were pretreated with 50nM ZVAD for 1hr before treatment with 4-Cl HIPP. Total
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protein lysates were analyzed by western blotting for PARP and caspase 3, and cleaved products
of each are noted. GAPDH was used as loading control.

Figure A2 4: 4-Cl HIPP upregulates pro-apoptotic gene expression. RNA isolated from HCT116
cells following 12hr treatment with 4-Cl HIPP was analyzed for Bik, PUMA, NOXA and BMF.
The fold change of mRNA levels in cells treated with 4-Cl HIPP was compared to mRNA levels
in vehicle cells.
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